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Cryotherapy is one of the popular treatments used to alleviate muscle soreness, 
especially in the competitive sports arena.  However, the therapeutic use of 
cryotherapy is unsubstantiated because of a lack of proper investigations in the 
literature, especially a hypothesised effect on muscle recovery.  Thus, our aims 
were to characterise satellite cell (SC) activity in human subjects with delayed 
onset muscle soreness (DOMS) and to shed light on the effect of cryotherapy on 
SC activity.  DOMS was induced in six male subjects (24 ± 3 years) by 
completion of a downhill-run (DHR) protocol (5 x 8 min bouts, 2 min rest 
between bouts) at 70 or 80% of their individual peak treadmill speed.  Ice 
application was applied to only one leg per subject for 3 days:  30 min every 2 
hours, 5 times per day.  In total 5 muscle biopsies were obtained from each 
subject: 1 baseline and 4 post-DHR.  Post-DHR biopsies:  1 from each leg on day 
1 and 7 (1st group, n=3) and 1 from each leg on day 2 and 9 (2nd group, n=3).  
DOMS was successfully induced as indicated by significant increases in muscle 
soreness at days 1 and 2 post-DHR (P < 0.01), and creatine kinase activity at day 
1 post-DHR (P < 0.01).  No difference in muscle soreness was found between 
treated and untreated legs.  SC quiescence and activation were characterised by 
their expression of the cell surface markers CD34 and CD56 respectively.  No 
significant change in quiescent SC was observed in the untreated or treated legs 
over time.  However, at day 1 post-DHR the number of quiescent SC was 
significantly lower in the untreated compared with the treated leg (P < 0.05). 
There was a significant increase in activated SC numbers at day 2 post-DHR in 
the untreated leg, which was sustained up to day 9 post-DHR (P < 0.01).  
However, no such increase was found in biopsies taken on days 1 and 7.  Also, no 
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change was found in the treated leg, however a significant difference between the 
number of activated SC in untreated and treated legs on days 2 and 9 post-DHR (P 
< 0.01) was seen.  No significant effect of DOMS or ice treatment was observed 
for the expression of the myogenic regulatory factors, MyoD and myogenin.  
C2C12 cell cultures induced to differentiate, however, did stain using these 
antibodies.  This is the first study to report an effect of cryotherapy at the tissue 
level.  In conclusion, this study highlights many unanswered questions on the SC 
response to DOMS at tissue level, and lays a good foundation for future studies. 
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Kreoterapie is een van die gewilde behandelings wat gebruik word om 
spierseerheid te verlig, veral in die kompeterende sport arena, maar die gebruik 
van kreoterapie is onbevestig as gevolg van ‘n gebrek aan voldoende ondersoeke 
in die literatuur, veral ‘n hipotese oor die effek op spier-herstel.  Ons doelstellings 
was dus om satellietsel (SC) aktiwiteit te ondersoek in mens proefpersone met 
vertraagde aanvang spierseerheid (DOMS) en ook om lig te werp op die effek van 
kreoterapie op SC aktiwiteit.  DOMS was in ses mans proefpersone (24 ± 3 jare) 
geїnduseer deur voltooїng van ‘n afdraend-hardloop (DHR) protokol (5 x 8 min 
rondtes, 2 min rus tussen rondtes) teen 70 of  80% van elkeen se individuele 
maksimum trapmeul-spoed.  Ys was vir 3 dae op net een been per proefpersoon 
aangewend:  30 min elke 2 ure, 5 keer per dag.  5 spierbiopsies in totaal was van 
elke proefpersoon verkry: 1 basislyn en 4 post-DHR.  Post-DHR biopsies:  1 van 
elke been op dae 1 en 7  (1ste groep, n=3) en 1 van elke been op dae 2 en 9 (2de 
groep, n=3).  DOMS was suksesvol geїnduseer soos aangedui deur die 
betekenisvolle verhogings in spierseerheid op dae 1 en 2 post-HR (P < 0.01) en 
kreatien kinase aktiwiteit op dag 1 post-DHR (P < 0.01).  Geen verskil in 
spierseerheid is gevind tussen die onbehandelde en behandelde bene nie.  SC 
dormansie en aktivering was gekarakteriseer deur die onderskeidelike uitdrukking 
van die sel oppervlak merkers CD34 en CD56.  Geen betekenisvolle verandering 
is in SC dormansie in die onbehandelde en behandelde bene waargeneem nie, 
maar op dag 1 post-DHR was die getal dormante SC betekenisvol laer in die 
onbehandelde been as in die behandelde been (P < 0.05).  Daar was ‘n 
betekenisvolle verhoging in die getalle geaktiveerde SC op dag 2 post-DHR in die 
onbehandelde been wat volgehou was tot op dag 9 post-DHR (P < 0.01), maar so 
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‘n verhoging was nie in biopsies wat op dae 1 en 7 geneem is gevind nie.  Daar is 
ook geen verandering in die behandelde been gevind nie, maar ‘n betekenisvolle 
verskil in die getal geaktiveerde SC is tussen die onbehandelde en behandelde 
bene op dae 2 en 9 post-DHR gevind(P < 0.01).  Geen betekenisvolle effek van 
DOMS en ys-aanwending vir die uitdrukking van die miogeniese (myogenic) 
regulatoriese faktore, MyoD en myogenin, is waargeneem nie.  C2C12 sel kulture 
wat geїnduseer is om te differensieer het wel gekleur vir hierdie antiliggame.  Dit 
is die eerste studie wat ‘n effek van kreoterapie op weefselvlak rapporteer.  Ten 
slotte, hierdie studie beklemtoon baie onbeantwoorde vrae oor die SC respons op 
DOMS op weefselvlak en dit lê ‘n goeie grondslag neer vir toekomstige studies. 
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CHAPTER 1:  INTRODUCTION 
 
Apart from the mechanical movements that are requirements for activities of daily 
life, skeletal muscle may be challenged by several stressors, including exercise, 
mechanical overloading and direct trauma.  These challenges can cause damage to 
skeletal muscle ranging from mild (micro-damage) to severe (e.g. a frank muscle 
tear).  Delayed onset muscle soreness (DOMS) is a form of micro-damage that 
typically manifests itself within one to two days following a session of 
unaccustomed exercise.  Skeletal muscle is very adaptable and is capable of 
responding to the above-mentioned stimuli via remodelling, regeneration and 
repair.  For example, upon overloading, as seen in weight training, skeletal muscle 
will enlarge by hypertrophy (Dangott et al., 2000) which is considered a form of 
remodelling, whereas upon direct muscle damage it will respond via the 
regeneration or repair pathways (Hurme & Kalimo, 1992).    
 
Although skeletal muscle fibres themselves are terminally differentiated, skeletal 
muscle regeneration is possible due to a special cell population, namely satellite 
cells, which is capable of promoting and facilitating the synthesis of new muscle 
proteins using a recurrence of the developmental pathways.  Hypertrophy and 
muscle repair can progress without activation of satellite cells, but via myonuclear 
upregulation of relevant proteins’ transcription and translation. Although the 
terms regeneration and repair are sometimes used interchangeably, some authors 
imply that the regeneration process requires the activation of the original 
embryonic pathways of muscle generation (Musaro et al., 2004). In adults, stem 
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cells are known to be able to differentiate along embryonic pathways (Bailey et 
al., 2001). Satellite cells are a stem cell-like population located between the 
sarcolemma and basal lamina of myofibres.   
 
1.1  Skeletal muscle  
1.1.1  Basic structure 
Skeletal muscle is composed of many elongated, cylindrical, multinucleated 
muscle cells known as myofibres.  These fibres are arranged parallel to each other 
and are bound together by three layers of connective tissue:  the epimysium, 
perimysium and the endomysium.  The epimysium surrounds a whole muscle (see 
Figure 1.1).  Within the muscle the myofibres are grouped into bundles (fasciculi) 
by the perimysium in which the muscle’s blood and nerve supplies are situated.  
Within the fasciculi each myofibre is surrounded by the endomysium which in 
turn is attached to the fibre cell membrane (sarcolemma) and conveys some of the 
contractile force to the tendons (McComas, 1996).   
 
The sarcolemma encases the muscle cell cytoplasm (sarcoplasm) that contains the 
muscle nuclei (myonuclei), mitochondria, energy substrates and the myofibrils.    
The sarcolemma forms a boundary between myonuclei (within a myofibre) and 
satellite cells (outside the myofibre) making it possible to distinguish between a 
myonucleus and the nucleus of a satellite cell (Mauro, 1961).  Satellite cells are 
sequestered between the sarcolemma and basal lamina of their associated 
myofibres (Mauro, 1961).  In addition to being a boundary between satellite cells 
and other cells outside of the myofibre (also aiding in identification of satellite 
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Figure 1.1  Basic structure of skeletal muscle.  A cross-section of skeletal muscle, 
showing the gross components and the structure of a sarcomere (A).  A satellite cell 
sequestered between the basal lamina and the sarcolemma of its associated myofibre (B). 
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cells) (Cooper et al., 1999), the basal lamina also plays a role in keeping the 
satellite cells in contact with their associated myofibres (Bischoff, 1990).   
 
Contraction of skeletal muscle is the responsibility of the myofibrils which consist 
mainly of the contractile proteins (myofiliments) myosin and actin.  These 
proteins are arranged into light and dark bands, consequently giving myofibres 
their striated appearance.  Myosin is associated with the dark bands (A-band) and 
actin with the light bands (I-band).  During relaxation, there is a region where the 
myosin and actin do not overlap, i.e. the H-zone.  This bands’ arrangement can be 
demonstrated in the smallest contractile unit of skeletal muscle, the sarcomere 
(refer to Figure 1.1).  Many of these sarcomeres are arranged end-to-end (ends 
indicated by the Z-line) to constitute a myofibril (Ganong, 1997b).  
Unaccustomed exercise may cause disarrangement of this banded structure, e.g. 
Z-line streaming or even Z-line disruption, both of which are associated with 
muscle micro-damage (Friden et al., 1981; Friden & Lieber, 1992).   
 
Calcium is required for muscle contraction and is stored in a tubular system, i.e. 
sarcoplasmic reticulum, that runs along the myofibres and also surrounds 
individual myofibrils (McComas, 1996). Muscle damage will cause disturbance to 
the sarcoplasmic reticulum, leading to an imbalance in calcium homeostasis 
(reviewed by Byrd, 1992).  Consequently an increase in intracellular calcium will 
activate certain enzymes (calpains) that may contribute to further muscle damage 
(reviewed in Belcastro et al., 1998).   
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1.1.2  Damage 
The response to severe acute muscle damage is similar irrespective of the cause 
and can be divided into several stages.  First, the disruption of the intracellular 
and/or extracellular compartments of the affected area occurs (Tidball, 1995).  
Calcium homeostasis within the severely damaged fibres is disrupted and 
autolysis of the damaged fibre components follows (Armstrong, 1990; Tidball, 
1995). In addition to myofibre damage, the connective tissue, nerves and blood 
vessels may also be disrupted.   If vascular disruption is present, platelets form a 
plug to close any damaged vessel.  This disruption phase causes several proteins, 
including enzymes and other factors, to be released into the circulation.  As 
reviewed by Tidball (1995), neutrophils are the first inflammatory cells to invade 
the injury site 1-6 hours following a severe insult.  Hereafter (9-12 hours after 
injury) monocyte and macrophage invasion accompanies the neutrophil invasion.  
12 hours after injury the neutrophil number starts to decrease with an increase of 
macrophages, which remain the predominant cell type (Tidball, 1995).  The 
macrophages not only remove the debris, but also secrete several factors and 
cytokines that might be important in the muscle repair and regeneration processes.  
The recovery phase from severe damage includes re-vascularisation (if any 
vascular damage occurred), as well as the proliferation and differentiation of 
satellite cells (and possibly other stem cells e.g. bone marrow-derived stem cells 
(Ferrari et al., 1998; LaBarge & Blau, 2002). 
 
Several of the factors released during the course of muscle damage have been 
identified as important factors in the activation of satellite cells, their proliferation 
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as well as their migration from undamaged to the damaged area (Tidball, 1995; 
Vierck et al., 2000).  These factors include hepatocyte growth factor (HGF), IL-6 
(interleukin 6), IL-1 (interleukin 1), leukaemia inhibitory factor (LIF), insulin, 
insulin-like growth factor (IGF-I), fibroblast growth factor (FGF), and vascular 
endothelial growth factor (VEGF) (Arsic et al., 2004; Germani et al., 2003; 
Vierck et al., 2000).  Some of these factors will be discussed in more detail later 
(see “Regulation of satellite cells”).  
  
The amount of inflammation caused by muscle trauma will depend on the severity 
of damage as well as the degree of vascularisation.  Muscle damage can be 
divided into macro-trauma (which includes crush injuries and moderate to severe 
sprains or strains) and micro-trauma that occurs with acute and chronic overuse 
syndromes (Merrick, 2002). Delayed onset muscle soreness (DOMS) has been 
shown to be associated with muscle micro-damage (Friden et al., 1983) and is 
experienced by most individuals at least once in their lifetime.  Thus it is relevant 
to study DOMS as a model of muscle damage in humans.  This model is not as 
extreme as some animal models of severe muscle injury, thus the processes of 
regeneration and repair may differ.  For example, the extent of, or even presence 
of embryonic or foetal contractile protein expression may differ, or the extent of 
the inflammatory response.  
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1.1.3  Delayed onset muscle soreness (DOMS) 
1.1.3.1  What is DOMS? 
Most of us have experienced the tender, aching and stiff feeling after going to the 
gym following a long absence, or after an unaccustomed bout of exercise, 
especially hiking.  Strangely this soreness only really becomes evident about 1-2 
days after the exercise bout, and usually continues for another 1-2 days.  This is 
what is known as DOMS.  DOMS occurs predominantly after unaccustomed 
eccentric (lengthening contraction) exercise (Byrnes et al., 1985a; Cleak & Eston, 
1992b).   
 
The clinical symptoms of DOMS include muscle soreness, muscle stiffness, 
swelling, decreased strength, tenderness on palpation (Cleak & Eston, 1992b; 
Eston et al., 1994; Eston et al., 1996b; Yackzan et al., 1984) and decreased active 
range of movement in the joints of the affected muscles (Yackzan et al., 1984).  
Although symptoms of DOMS may become evident within 8-12 hours after the 
exercise bout (Nosaka & Kuramata, 1991), in general these symptoms peak a day 
or two days (24-48 hours) post-exercise whereafter they resolve within a day or 
two (Pizza et al., 1995; Thompson et al., 1999).  In extreme cases however, 
DOMS may peak only at five days and require a further five days to resolve 
(Manfredi et al., 1991).  These differences in peak and duration times of DOMS 
infer that the type and extent of exercise plays a role in the severity of DOMS. It 
has been reported that the intensity, rather than the duration, of an exercise is the 
determining factor in inducing DOMS (Tiidus & Ianuzzo, 1983).  Interestingly, 
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type II fibres have been reported to be more susceptible to the micro-damage 
associated with DOMS (Friden et al., 1983).  
 
In most studies, plasma or serum creatine kinase (CK) activity is used as a 
measure of muscle damage (Schwane et al., 1983; Tiidus & Ianuzzo, 1983).  
Although used as an indicator of muscle damage, CK activity is not a predictor of 
the extent of muscle damage, but merely the presence of some damage.  Data have 
shown no linear statistical correlation between CK activity and the extent of 
muscle damage (Manfredi et al., 1991), nor between CK activity and muscle 
soreness (Nosaka & Kuramata, 1991). This is also confirmed by data showing that 
muscle tenderness is not associated with serum CK activity (Eston et al., 1994).  
Although CK activity is the general blood parameter measured to indicate muscle 
damage in DOMS studies, other studies have measured proteins such as lactate 
dehydrogenase (LDH) (Schwane et al., 1983), malondialdehyde (MDA - a free 
radical production indicator) (Eston et al., 1996a) and myoglobin (Byrnes et al., 
1985b).  
 
1.1.3.2  Pain associated with DOMS  
Several theories postulating the pathophysiology of pain associated with the 
syndrome of DOMS suggest that connective tissue damage, inflammation and 
sarcomere damage may all play a role.  Alternatively, physiological conditions 
such as lactic acid accumulation and muscle spasms may cause pain. However, 
lactic acid has been shown not to be the culprit and data on muscle spasms are 
inconclusive.  Although muscle damage and inflammation are both associated 
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with DOMS, a cause-effect relationship has not been established (reviewed in 
Cleak & Eston, 1992a). Recent data implicate the role of muscle 
mechanoreceptors in generating pain during DOMS (Weerakkody et al., 2001; 
Weerakkody et al., 2003).   
 
In their 2001 study (Weerakkody et al., 2001), the authors induced DOMS in one 
leg of human subjects using a protocol consisting of walking backwards on an 
inclined (13o) moving treadmill.  Subjects had to step backward using the toe-to-
heel movement which caused eccentric contraction in the triceps surae (DOMS 
leg).  The other leg was placed flat alongside which did not cause eccentric 
contraction in the triceps surae.  Some subjects received isotonic saline injections 
before and after the exercise bout.  The rationale being that if the nociceptors 
(pain receptors) were sensitised during DOMS, these injections could cause an 
increase in pain in the DOMS leg.  However, no significant difference in pain 
experienced was found between the exercised and non-exercise leg, thus 
excluding a role for nociceptors in pain during DOMS.  In another group of 
subjects, vibration (20 and 80 Hz) was applied to the muscle.  This caused an 
increase in pain in the exercised leg with more pain experienced at 80 Hz.  These 
authors suggest that their data indicate the involvement of primary muscle spindle 
endings in pain during DOMS.  To control for possible skin sensations, an 
anaesthetic cream was applied to three subjects, showing that skin sensation did 
not play a role in perceived pain sensation.  Some subjects also participated in a 
nerve block experiment.  Blocking the sciatic nerve was achieved by placing a 
wooden bar under the exercised thigh (distal to the ischial tuberosity) with the 
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subjects leaning towards the bar with their full body weight.  Pain sensation 
significantly decreased with this nerve compression block, whereas latency for hot 
and cold sensation was unchanged.  In summary, these authors concluded that 
muscle mechanoreceptors, including muscle spindles, are involved in generating 
pain during DOMS.   
 
In 2003, this research group conducted a similar study (Weerakkody et al., 2003) 
with some modifications.  The same one-legged backward walking protocol was 
used to induce DOMS in one leg.  They included the vibration test in the saline 
and nerve block groups, as well as including vibration and saline injection during 
a nerve block.  Vibration in the DOMS leg, with added saline, increased the 
perceived pain.  Furthermore, the nerve block was capable of reducing pain, even 
when vibration was applied.  In conclusion, these authors speculate that large-
diameter mechanoreceptive afferents in muscle are involved in generating pain 
during DOMS.  
 
1.1.3.3  Possible DOMS treatments 
Treatments for the soreness and stiffness associated with DOMS that are currently 
used include massage (Lightfoot et al., 1997; Smith et al., 1994b; Tiidus & 
Shoemaker, 1995), passive stretching (Lund et al., 1998), pulsed ultrasound 
(Hasson et al., 1990), cryotherapy (Paddon-Jones & Quigley, 1997), anti-
inflammatory and analgesic drugs (Francis & Hoobler, 1987; Hasson et al., 1993; 
Lecomte et al., 1998; Tokmakidis et al., 2003; Trappe et al., 2001), hyperbaric 
oxygen therapy (Mekjavic et al., 2000; Staples et al., 1999), vitamin C 
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supplementation (Childs et al., 2001; Kaminski & Boal, 1992; Thompson et al., 
2001), a fabric with electromagnetic shielding properties (Farabloc) (Zhang et al., 
2000), exercise (Carpinelli & Gutin, 1991; Jamurtas et al., 2000) and 
homoeopathic medicine (Vickers et al., 1997).  Ingestion of non-steroidal anti-
inflammatory drugs is a popular treatment used for DOMS (Donnelly et al., 1990; 
Hasson et al., 1993; Semark et al., 1999).  However, data regarding these non-
steroidal anti-inflammatory drugs are conflicting. In one study ibuprofen was not 
effective in alleviating muscle soreness or increasing muscle strength in people 
suffering from DOMS (Donnelly et al., 1990), whereas another study found that 
ibuprofen can indeed decrease muscle soreness (Tokmakidis et al., 2003).  The 
latter study however also found ibuprofen to be ineffective in improving muscle 
strength after a DOMS-inducing exercise bout.  In the study by Donelly et al. it 
was found that the serum CK activities and urea concentrations were higher in the 
ibuprofen-treated group than the placebo group.  This infers that, apart from being 
ineffective in enhancing muscle recovery after a DOMS-inducing exercise, 
ibuprofen may also exacerbate muscle damage.    
 
Studies have shown smaller changes in muscle soreness and serum proteins (e.g. 
CK, myoglobin) when a second bout of exercise follows the first (Byrnes et al., 
1985b; Donnelly et al., 1990; Eston et al., 1996a).  This suggests that the first 
bout of exercise has a prophylactic effect on the second, decreasing muscle 
soreness and serum protein levels (Byrnes et al., 1985b; Donnelly et al., 1990; 
Eston et al., 1996a).  This is known as the second bout effect and the effectiveness 
of the first bout seems to depend on the type of exercise, e.g. the protective effect 
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of isometric exercise only lasts about 3 weeks (Triffletti et al., 1988) whereas the 
prophylactic effect of an eccentric exercise bout lasts up to 6 weeks (Byrnes et al., 
1985b).  Newham and his colleagues (Newham et al., 1987) showed that the 
recovery rate of strength and force-frequency parameters of skeletal muscle also 
improved with the second and third bout of exercise.  In this study, where the 
bouts were performed two weeks apart, plasma CK activity did not significantly 
change from baseline values after the second and third bouts.  When an eccentric 
bout of exercise is repeated 48 hours after the first, the time-course and severity of 
muscle soreness, serum CK activity and muscle strength is similar in both the first 
and second bout (Smith et al., 1994a).   
 
The use of cryotherapy dates back to the ancient Greeks and Romans.  
Cryotherapy is a collective term for all cold treatments, including ice massage, ice 
packs, cold packs, gel packs, and ice-water baths (Knight, 1995).  There is much 
controversy about whether it works to reduce muscle soreness or not.   
 
1.1.3.4  Cryotherapy 
Cryotherapy causes vasoconstriction, decreases microvascular permeability as 
well as oedema (Knight, 1995).  The effect of cryotherapy on blood vessel 
diameter is variable.  Initially cryotherapy will cause vasoconstriction, but after 
long exposure (after 15 – 40 minutes of cold exposure) to cold temperatures 
vasodilation will occur (cold-induced vasodilation) (Knight, 1995; Mac Auley, 
2001).  It is believed that this vasodilatation is a reflex to protect the muscle 
against cold damage.  Cryotherapy’s effect on the vasculature also seems 
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dependent on whether it is applied as a therapeutic intervention or not.   Without 
any injury a cold application will decrease blood flow (Curl et al., 1997; 
Karunakara et al., 1999), but when applied to muscle after contusion injury no 
vasoconstriction occurs (Curl et al., 1997 ) Cryotherapy is also believed to 
decrease inflammation (Knight, 1995) as well as secondary injury (Merrick et al., 
1999).  In addition to cryotherapy decreasing microvascular permeability, and 
thus oedema, data also show that cryotherapy decreases interaction between 
leukocytes and endothelial cells that may contribute further to the decrement in 
oedema after cryotherapy (Deal et al., 2002).   
 
The literature on the use of cryotherapy as a therapeutic intervention is inadequate 
(MacAuley, 2001; Mac Auley, 2001).  It is also difficult to compare results of 
different studies due to the wide range of cryotherapy protocols used.  The cooling 
effect of cryotherapy depends on the type of cold application (e.g. ice bag, or ice 
massage) (Zemke et al., 1998), duration of application (MacAuley, 2001; Mac 
Auley, 2001), and adipose tissue (Myrer et al., 2001).  The size of the muscle 
group is also a contributing factor, because the deeper tissues, and thus a larger 
muscle, will need more time to cool down (Knight, 1995; Myrer et al., 2001; 
Zemke et al., 1998). 
 
1.2 Skeletal muscle regeneration 
Satellite cells, unlike their neighbouring myofibres, are capable of entering the 
mitotic cycle, an important factor for both muscle growth and regeneration.  
Satellite cell progeny fuse with existing myofibres, become true myonuclei (Moss 
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& Leblond, 1971) and thereby facilitate muscle growth and repair.  Whether or 
not the satellite cells are highly involved in muscle hypertrophy in adults is still 
controversial.  
 
1.2.1  Muscle growth and hypertrophy 
The proliferation and fusion of satellite cells are responsible for myonuclei 
accretion during muscle growth.  In the study by Moss and Leblond (1971), 
growing rats (14-17 days) were injected with a radioisotope to investigate muscle 
sections (radioautography) at 1, 18, 24, 48, and 72 hours after injection.  Their 
results confirmed that myonuclei do not proliferate, but satellite cells are capable 
of DNA synthesis.   
 
In a study by Kadi and Thornell it was shown that short-term (10 week) strength 
training can induce an increase in myonuclei (70%), as well as satellite cell (46%) 
number in human (female) trapezius muscles, in addition to increasing fibre size 
(Kadi & Thornell, 2000).  It was suggested that the acquisition of myonuclei is 
important to assist hypertrophy after the strength-training program.  A significant 
positive relationship between the proportion of satellite cells/mm2 and the number 
of myonuclei/mm2 (r=0.5) was found, however no distinction between quiescent 
and activated satellite cells was made in this study.  Thus, it is unclear whether a 
10-week strength training program increases the quiescent satellite cell pool in 
addition to increasing the activated satellite cells.  An increase in satellite cell 
number (quiescent and activated) may be advantageous during training to 
‘prepare’ for possible future muscle injuries, i.e. to allow for a better regenerative 
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response.  Alternatively, the training may have caused unacknowledged micro-
damage with subsequent satellite cell proliferation.  Finally, it may be possible 
that the satellite cell pool has been enhanced by circulating stem cells (Ferrari et 
al., 1998; LaBarge & Blau, 2002).  The following section explains the concept of 
stem cells in more detail. 
 
1.2.2  Cell biology and stem cells 
Stem cells are present in mammals during the development stage, as well as 
during post-natal and adult life (Figure 1.2).  In fact, each one of us started as a 
totipotent stem cell, i.e. the zygote.  For a cell to be recognised as a stem cell it 
first has to fulfil specific criteria.  Stem cells are capable of self-renewal (by 
proliferation) and they are capable of differentiating into more than one type of 
tissue (multilineage differentiation) (Jankowski et al., 2002).  Cells of the zygote 
and the early blastocyst are totipotent, meaning that they are capable of producing  
a complete organism.  Pluripotential cells are capable of forming the three germ 
layers, but cannot give rise to a complete adult organism (extra embryonic and 
embryonic tissue).  Multipotential stem cells cannot develop into all three 
embryonic germ layers, but are capable of multilineage differentiation (Jankowski 
et al., 2002; Lodish et al., 2004), whereas an unipotent stem cell is capable of self-
renewal and producing only one cell type (Lodish et al., 2004).  Adult stem cells 
are stem cells obtained from the different tissues in an organism post-natally.  
Refer to Figure 1.2 for a schematic presentation of the different stem cell types, as 
well as Table 1.1 for definitions of different stem cells. 
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Figure 1.2.  Stem cell potency during development. 
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Table 1.1  Different stem cell definitions.  This table was taken from a journal 
article (Niesler, 2004) with the permission of the author, Dr. Carola U. Niesler. 
 
 
STEM CELL AND PROGENITOR CELL DEFINITIONS
Adult Stem Cell An unspecialised cell, derived from a 
postnatal animal,  capable of self renewing 
AND generating specialized mature cells 
Hematopoietic Stem Cell A stem cell, which can proliferate and 
differentiate into mature blood cells. 
Mesenchymal Stem Cell A stem cell, which can proliferate and 
differentiate into mesenchymal tissues 
(such as bone, cartilage, muscle) 
Mesodermal Progenitor Cell An unspecialised cell capable of yielding 
mesodermal tissue (such as muscle).  
Progenitor cells are not capable of self-
renewal. 
Hemangioblast Earliest mesodermal precursor of both 
blood and vascular endothelial 
Angioblast An endothelial cell progenitor cell. 
Multipotent Adult Progenitor Cell  Cells isolated from postnatal bone marrow 
that can differentiate into mesodermal, 
neuroectodermal and endodermal cells in 
vitro and into all embryonic lineages in 
vivo 
 
 
 
Skeletal muscle contains a special cell population situated only in skeletal muscle, 
namely the satellite cells.  These cells are mononucleated (Bailey et al., 2001; 
Hughes & Blau, 1990) and located between the basal lamina and basement 
membrane (one of the layers of the sarcolemma (McComas, 1996)) of each 
skeletal muscle fibre (Bailey et al., 2001) (Figure 1.1) Under normal conditions 
satellite cells are mitotically quiescent (Seale & Rudnicki, 2000), but are capable 
of maintaining or increasing their pool by proliferation (Hawke & Garry, 2001).  
Numerous stimuli, e.g. stretch, muscle damage, and exercise are capable of 
activating satellite cells in humans (Crameri et al., 2004; Kadi et al., 2004b), as 
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assessed by immunohistochemistry, and in animal models (Darr & Schultz, 1987), 
as assessed by autoradiography. 
 
Although satellite cells have functional characteristics of stem cells, authors 
disagree on whether they are truly adult stem cells or whether they are progenitor 
cells (see Table 1.1 for definition).  Satellite cells will therefore be referred to as 
stem cell-like cells, rather than stem cells.   
 
1.2.3  Satellite cells 
1.2.3.1  Cell cycle 
In normal adult skeletal muscle, satellite cells reside in the G0 phase, i.e. they are 
mitotically quiescent.  Under appropriate conditions these cells become activated, 
start to proliferate and differentiate into myoblasts.  After proliferation the 
myoblasts can fuse with each other or with an existing myofibre.  During the 
different phases of the cell cycle satellite cells express distinct proteins that help 
to identify in which phase these cells exist.  These cycle markers include CD34 
(expressed by most quiescent satellite cells) (Beauchamp et al., 2000), CD56 
(expressed predominantly by activated satellite cells) (Malm et al., 2000), MyoD 
(expressed by proliferating satellite cells) (Cooper et al., 1999), and myogenin 
(expressed by differentiating satellite cells) (Rantanen et al., 1995).  For this 
whole process of satellite cell activation, proliferation, and differentiation, many 
growth factors and cytokines are needed. 
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1.2.3.2  Model systems 
Cell cultures are a good model for studying different aspects of muscle 
regeneration and through them much can be learned about satellite cells’ 
responses to stimuli during the activation, proliferation and differentiation 
processes.  However, application of this information to the regeneration process in 
vivo is difficult and must be approached with caution.  In some circumstances the 
effects in vivo contradict what has been observed in vitro.   
 
Different cell lines are often used to investigate the response of muscle to damage 
or stress in vitro, for example C2C12 cells are specifically used to investigate 
satellite cells.  It is also possible to study satellite cells in single myofibre cultures 
(Bischoff, 1990; Li et al., 2000).  Bischoff (Bischoff, 1986) designed a protocol to 
study satellite cells in vitro.  This protocol entailed the isolation of muscle fibres 
with their associated satellite cells still intact.  In cell culture, the proliferating 
satellite cells do not detach from their associated muscle fibre, but their numbers 
increase to cover the entire myofibre.  This culture method of intact fibres is a 
better simulation of the in vivo state of satellite cells compared to cultures of 
satellite cells in the absence of mature myofibres.  It has been shown in isolated 
muscle fibre cultures that complete skeletal muscle myofibre regeneration can 
occur in the presence of satellite cells alone (without the need for other stem or 
progenitor cells) (Zammit et al., 2002). 
 
Animal models which allow for gene manipulation, to delete or inactivate specific 
genes of interest, make it possible to investigate the specific roles of their products 
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in vivo.  For example, by inactivating the fibroblast growth factor 6 gene, Floss 
and his colleagues have shown that this growth factor is important for muscle 
regeneration (Floss et al., 1997).  It is also possible to modify a specific gene so 
that cells can be tagged and easily identified.  An example of such a gene 
modification is that of transgenic desmin nls lacZ mice (Lescaudron et al., 1997; 
Lescaudron et al., 1999), where all cells expressing desmin are positive for lacZ 
and can therefore be identified by the addition of X-gal.  In this model desmin is 
only expressed during embryonic development and during muscle regeneration in 
adults.  Without, or in combination with these models, it is necessary to identify 
satellite cells or satellite cells by other means.     
 
1.2.3.3  Identifying satellite cells 
A number of techniques can be used to identify satellite cells in skeletal muscle 
sections.  Most commonly, electron microscopy (EM) and light microscopy are 
used.  Labelling certain biological elements with radioactive isotopes or a 
nucleotide analogue can be used to identify targeted molecules or structures.  For 
example, 3H-labelled thymidine or bromodeoxyuridine (BrdU, a thymidine 
analogue) will be incorporated into the nuclei of proliferating cells (Hurme & 
Kalimo, 1992; Rantanen et al., 1995). Both light and electron microscopy are used 
to visualise these labelled nuclei.  However, using only light microscopy will not 
allow one to distinguish between proliferating satellite cells and proliferating 
fibroblasts (or any other proliferating cell in close proximity to myofibres), thus 
care should be taken when using only light microscopy in skeletal muscle sections 
when investigating satellite cells.   
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 a)   Electron microscopy (EM) 
Satellite cells were first discovered by Mauro (Mauro,1961) using EM.  EM is a 
very valuable tool to investigate cells at ultra-structural level and to gather 
morphological information.  Using EM, satellite cells are identified by their 
location between the basal lamina and sarcolemma of a myofibre.  Distinction can 
be made between quiescent and activated satellite cells based on their differences 
in morphological and morphometric appearances.  In transverse sections, 
quiescent satellite cells’ nuclei occupy most (about 60%) of their surface areas 
with their plasmalemmae separated from their associated myofibres’ 
sarcolemmae.  When satellite cells become activated, they enlarge or elongate 
with an accompanied decrement in the nucleus to cytoplasm ratio (Gregory & 
Mars, 2004).   
 
b)   Light microscopy 
Dyes and stains commonly used for light microscopy (e.g. hematoxylin, eosin) do 
not enable identification of satellite cells.  Immunohistochemistry (the use of 
antibodies in conjunction with microscopy) on the other hand, can be used to 
identify satellite cells.  Antibodies against laminin (located in the basal lamina) 
(Bischoff, 1986) or dystrophin (located within the sarcolemma) (Ganong, 1997b) 
are commonly used to identify satellite cells by their location (between the basal 
lamina and sarcolemma).  With the fairly recent discovery of specific markers for 
satellite cells, especially in the last decade, and the commercial availability of 
antibodies to identify these markers, it has now also become possible to identify 
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satellite cells themselves immunohistochemically in skeletal muscle sections.  
Antibody binding can be demonstrated using non-fluorescent dyes, such as 
diaminobenzidine (DAB) (bright-field microscopy) (Cooper et al., 1999; Kadi & 
Thornell, 2000) or fluorescent substances such as Texas Red or FITC (dark-field 
microscopy) (Cooper et al., 1999; Crameri et al., 2004; Kadi et al., 2004b).  
Satellite cell markers and their distribution are listed in Table 1.2.    
 
Controversy still exists surrounding some of these markers (and this will be 
highlighted whenever appropriate in the following sections) due to the recent 
nature of immunohistochemistry as a technique to identify satellite cells.  These 
controversies are due to different laboratories using different models, e.g. cell 
cultures versus muscle tissue sections, to investigate expression of these markers.  
Furthermore, different research groups use antibodies developed by different 
companies, or some research groups develop their own antibodies.  Satellite cell-
specific antibodies are a fairly new concept and the development process of more 
sensitive (and even new) antibodies is quite fast, thus also contributing to the 
controversies.  As can be seen from Table 1.2, markers are localised in various 
areas of the satellite cell’s structure.  Some markers are specific for only one 
phase of the cell cycle, e.g. CD34, whereas most markers are expressed in satellite 
cells at several stages of their cell cycle, e.g. m-cadherin.  Co-staining with two or 
three antibodies (satellite cell specific or for another protein) is advisable to 
ensure positive identification of satellite cells.  Often laminin, which stains the 
basal lamina, is used in conjunction with a satellite cell marker to exclude any 
positively stained cell that lies outside the boundaries of the myofibre (Rantanen 
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et al., 1995).  On the other hand it must be taken into account that both the 
myonuclei and satellite cell nuclei lie within the boundary of the basal lamina, and 
although myonuclei lie beneath the sarcolemma and satellite cell nuclei outside  
 
Table 1.2  List of possible satellite cell markers adapted and modified from 
Hawke & Garry (2001) and Charge & Rudnicki (2004).   
 
Marker Expression in SC*  Localisation ref 
CD34 Quiescent membrane 2 
CD56 (NCAM, Leu19) quiescent, activated, proliferating membrane 1, 2 
MyoD (Myf3) activated, proliferating nucleus 1, 2 
Myogenin (Myf4) Differentiating nucleus  
M-cadherin quiescent, activated, proliferating membrane 1, 2 
    
MNF quiescent, activated, proliferating nucleus 1, 2 
Pax7 quiescent, activated, proliferating nucleus 1, 2 
c-Met quiescent, activated, proliferating membrane 1, 2 
VCAM-1 quiescent, activated, proliferating membrane 1, 2 
Desmin activated, proliferating cytoskeletal 1, 2 
Myf5 (quiescent), activated, proliferating nucleus 1, 2 
Syndecan-3 quiescent, activated, proliferating membrane 2 
Syndecan-4 quiescent, activated, proliferating membrane 2 
MSTN Quiescent, (proliferating) nucleus 2 
IRF-2 Quiescent, proliferating nucleus 2 
Msx1 Quiescent nucleus 2 
 
 * Expressed in growing or adult organisms 
1. (Hawke & Garry, 2001) 
2. (Charge & Rudnicki, 2004)  
 
Abbreviations:   MNF, myocyte nuclear factor 
NCAM, neural cell adhesion molecule 
VCAM, vascular cell adhesion molecule 
PCNA, proliferating cell nuclear antigen 
MSTN, myostatin 
IRF-2, interferon regulatory factor-2 
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 the sarcolemma, the distinction between the sarcolemma and basal lamina is not 
that clear with light microscopy.  Thus, laminin may not be the best co-stain to be 
used with other satellite cell markers, especially when staining with satellite cell 
nuclear markers 
 
c)   EM versus Immunohistochemistry 
Both these methods of visualising satellite cells have their advantages and 
disadvantages.  EM is useful and very reliable for accurate identification of cells 
and other structures, but is not very useful for quantitative studies as few cells are 
viewed in each field.  Furthermore, EM cannot be used to identify the different 
phases that a satellite cell may find itself during regeneration, except for quiescent 
and activated satellite cells (Gregory & Mars, 2004).  Immunohistochemistry on 
the other hand is more useful for quantitative studies (larger number of cells per 
field of view), but cannot identify satellite cells with the same accuracy as EM.  
The latter is due to the fact that the basal lamina and sarcolemma are not 
distinguishable with light microscopy.  EM is very time consuming, because the 
visible field under the microscope is very small, thus it will take longer to view a 
large area.   
 
1.2.3.4  Regulation of satellite cell activity 
The exact mechanisms involved in satellite cell activation are not well understood.  
Satellite cells on a myofibre can be activated in the absence of necrosis of the 
myofibre (Darr & Schultz, 1987).  Furthermore, activation is not always 
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accompanied by proliferation or differentiation.  For example, a bout of exercise 
can induce satellite cell activation without evidence of proliferation and 
differentiation (Crameri et al., 2004).  
 
Satellite cell activation following exercise has been investigated in young (1 
month old) compared to mature (3 month old) rats (Darr & Schultz, 1987).  At 
days 1, 2, 3, and 5 post-exercise, the soleus and extensor digitorum longus 
muscles were analysed for satellite cell activation making use of autoradiography.  
Activation peaked a day earlier in mature rats than in young growing rats.  In 
addition, the peak of activation differed between the two muscle groups within the 
mature group, with the peak occurring at day 1 for the soleus and day 2 for the 
extensor digitorum longus muscle.  Even though a small number of fibres showed 
some evidence of degenerative and necrotic features (characterised by infiltration 
of fibres by macrophages and mononuclear cells), it was not only these fibres that 
had satellite cell activation.  Fibres without lesions also displayed an increase in 
satellite cell activation post-exercise.  Whether this activation is due to the 
mechanical or cytokine effects of exercise, or both, is not clear.   It is also not 
clear why the different muscles demonstrated different time courses, or why the 
age of the rats influenced the time course of satellite cell activation. 
 
a)  Satellite cell-myofibre contact 
Bischoff (Bischoff, 1990) has indicated that the contact between a satellite cell 
and its mature myofibre might play a role in regulating the state of the satellite 
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cell.  Specifically it seems that the mature myofibre might reduce proliferation of 
satellite cells in contact with it.  This suggests one or more of the following: 
1. The myofibre produces a factor(s) following damage that activates the 
satellite cells. 
2. Damage to the sarcolemma itself will disturb contact between the satellite 
cell and myofibre which will then activate the satellite cell. 
3. Another myofibre produce cytokines to activate satellite cells. 
4. Friction due to mechanical stretching by exercise may activate satellite 
cells. 
Bischoff et al. were unsuccessful in culturing satellite cells in the presence of the 
sarcolemma, but in the absence of the basal lamina.  In the absence of the basal 
lamina the satellite cells cannot stay intact with myofibres.  Crushed muscle 
extract (acting as mitogen) was required to activate satellite cell growth.  However 
satellite cells in contact with both the basal lamina and plasmalemma (live 
myofibre) are about 40% less responsive to mitogen compared to satellite cells 
which are not.  Therefore contact is important for satellite cell proliferation, but 
activation may require the basal lamina to become permeable to certain growth 
factors.   
 
Once satellite cells are activated, they may start to proliferate and some of the 
progeny may differentiate into muscle cells.  These latter processes are under 
control of the myogenic regulatory factors (MRFs).  The MRFs include Myf5, 
MyoD (Myf3), myogenin (Myf4), and MRF4 (Myf-6/herculin) (Kerst et al., 2000) 
which are members of the myogenic basic helix-loop-helix (bHLH) family of 
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transcription factors (Alberts et al., 1983; Bailey et al., 2001).  These transcription 
factors are involved during the development of skeletal muscle, but are also 
involved in satellite cell differentiation and maturation postnatally (Table 1.3). 
 
Table 1.3  Summary of myogenic regulatory factors (MRFs). 
 
MRF Function Expression during SC cell cycle 
 
Myf5 
 
 
 
May be involved in SC self-renewal 
 
quiescence/activation 
MyoD 
 
 
Very important for SC progression to 
terminal differentiation 
proliferation 
Myogenin 
 
 
Important for differentiation differentiation 
MRF4 
 
 
May play role in muscle fibre 
maturation 
fusion 
 
 
b)  Myf5 and MyoD 
Sabourin et al. (Sabourin et al., 1999) used primary cultures of wild-type vs 
MyoD deficient mouse skeletal muscle to investigate the differentiation potential 
of MyoD-/- myogenic cells.  The finding that MyoD deficient cells displayed a 
reduced differentiation potential, substantiates the view of MyoD being an 
important factor in myogenic determination.  Their results also indicated that 
Myf5, although also a MRF, cannot substitute the function of MyoD.   
 
Cooper and his colleagues (Cooper et al., 1999) showed that activated murine 
satellite cells express either MyoD or Myf5, or both in vivo.  They also showed 
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that MyoD is expressed by all proliferating satellite cells.  I propose that the 
difference between these two populations of satellite cells may be that those 
satellite cells expressing MyoD early are somehow primed to proliferate and 
differentiate immediately when stimulated, while those that express Myf5 support 
the quiescent satellite cell pool.  This would infer that those expressing both 
MyoD and Myf5 can proliferate and differentiate as well as maintain the quiescent 
satellite cell pool (depending on the stimulus).   Apart from the authors’ findings 
and conclusions their results suggest the existence of three distinct populations of 
satellite cells in vivo: MyoD+, Myf5+, MyoD+/Myf5+.  However, in cell culture, 
nearly all (>98%) activated satellite cells were shown to express both MyoD and 
Myf5 at 24 hours (Zammit et al., 2002).  The latter study infers that data obtained 
from in vitro models may not always be absolutely applicable to the in vivo 
situation.   
 
The possibility of more than one satellite cell population was hypothesised a few 
years earlier by Rantanen and his colleagues (Rantanen et al., 1995).  In the study 
by Rantanen et al., desmin-, MyoD- and myogenin positive nuclei were detected 
in rat skeletal muscle after damage before BrdU (indication of proliferation) was 
detected.  These authors proposed that one population is ready for immediate 
differentiation, without proliferation (‘committed’ satellite cells).  The other 
population undergoes mitosis prior to dividing into one daughter cell for 
differentiation and another for future proliferation (‘stem’ satellite cells).  
However, they did not address the possibility of unequal expression of receptors 
for satellite cell activation factors on distinct satellite cell populations.  If this was 
 28
the case, different activators may stimulate the distinct populations. It would be 
valuable to determine whether receptor expression levels can be correlated to 
different satellite cell populations.  To date no research group has investigated this 
possibility.  Recently an electron microscopy study of monkey skeletal muscle 
showed two patterns of satellite cell activation after ischaemia and reperfusion.  
These authors concluded that these two different responses in satellite cell 
activation may either represent different functions or may infer the existence of 
two satellite cell populations (Gregory & Mars, 2004).   
 
The possibility that two distinct satellite cell populations exist should not be 
confused with the fact that skeletal muscle (and other tissues) also have a pool of 
side population (SP) cells.  This muscle SP cell pool is a population of stem cells 
that can be purified from skeletal muscle by fluorescence-activated cell sorting 
(FACS) and that can be identified by their exclusion of the DNA dye, Hoechst 
33342.  This population expresses the hematopoietic stem cell marker Sca-1 and 
may also express another hematopoietic marker, CD45.  Muscle SP cells are 
capable of differentiating into hematopoietic cells, muscle cells and satellite cells 
(reviewed by Asakura, 2003).  In contrast, committed satellite cells don’t express 
these particular hematopoietic stem cell markers.  
 
Cornelison and Wold (Cornelison & Wold, 1997) investigated the expression of 
all MRFs in single murine satellite cells still attached to their myofibres.  Their 
study indicated that c-met mRNA is expressed by all satellite cells in fibre 
cultures, but m-cadherin mRNA is expressed initially during activation in only a 
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small fraction (<20%) of satellite cells.  They have also shown that there was no 
significant difference in c-met and m-cadherin mRNA expression between 
satellite cells from predominantly fast and slow fibres.  All MyoD- or myogenin-
positive cells expressed c-met.  The conclusion was that c-met is expressed by 
quiescent satellite cells (intact muscle) and during the different phases after 
activation (fibre culture).   
 
c)  Myogenin  
It has been shown that myogenin protein expression increases during the 
differentiation phase of the satellite cell cycle.  To date the function of myogenin 
is unclear.  Myogenin knockout animals are not viable.  The reason for 
unsuccessful breeding is due to the fact that myogenin-mutant mice die 
immediately after birth.  These mutant animals also have a reduction in size of all 
skeletal muscles.  This infers the essential role of myogenin for the functional 
development of skeletal muscle (Hasty et al., 1993). 
 
Myogenin has been analysed in adult rats in response to contusion and toxic 
muscle injury.  Traumatic contusion damages the connective tissue and the 
vasculature whereas notexin (toxin) only damages the myofibres without 
damaging the blood vessels and nerves.  Although the toxic injury induced less 
muscle damage, muscle regenerating events after both injury models were very 
similar.  Mitotic activity, as indicated by BrdU-positive nuclei, was detectable at 
24 hours post-injury.  Myogenin positive satellite cell nuclei were detectable at 12 
 30
hours post-injury and expression increased 5-fold at 36 hours post-injury 
(Rantanen et al., 1995).  
 
d)  MRF4 
MRF4 (alternatively known as Myf6 or herculin) protein was found to be present 
prior to and after fusion in regenerating myofibres, but not in satellite cells.  This 
suggests that MRF4 is important for myofibre fusion, but does not play a role in 
satellite cells during proliferation prior to differentiation (Zhou & Bornemann, 
2001).  In a recent study it was concluded that MRF4 is also a determination gene 
for the myogenic lineage.  This became evident when Myf5:MyoD double mutant 
mice developed skeletal muscle only if the MRF4 gene was not deleted as well 
(Kassar-Duchossoy et al., 2004). 
 
In addition to the MRFs needed for maintaining satellite cells in their cell cycle, 
other factors are needed to regulate the expression of MRFs as well as the 
migration and activation of satellite cells.  For example, myoblasts are capable of 
migrating across the basal lamina, even in the absence of muscle damage (Hughes 
& Blau, 1990).  Some of these factors will be discussed in the following section. 
 
e)  Growth factors  
The majority of studies on growth factors have been conducted using primary 
satellite cell cultures, or myoblast cell lines derived from satellite cells (e.g. 
C2C12 cells).  Most growth factors have no effect on quiescent satellite cells of 
adult muscle in vivo as long as their myofibres are intact.  Plasma membrane 
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damage therefore in some way primes the satellite cells thereby making them 
responsive to growth factors.  The only exception is hepatocyte growth factor 
(HGF) (also known as scatter factor, SF) which is able to activate quiescent 
satellite cells, even in the absence of muscle damage (Tatsumi et al., 1998).   
 
Crushed human muscle has the ability to stimulate proliferation, alignment and 
fusion of C2C12 cells (Li et al., 2000).  These authors identified that this ability 
could be attributed to a ~ 40 kDa protein in a fraction of the muscle extract.  The 
fraction containing this unidentified protein stimulated regeneration even when 
injected into rats after strain-induced muscle injury.  Tatsumi et al. identified the 
unknown satellite cell activator found in crushed muscle extract to be HGF 
(Tatsumi et al., 1998).  Although HGF is a 90 kDa protein the 40 kDa protein 
identified by Li et al. (Li et al., 2000) may be a subunit of HGF. 
 
In addition to acting as an activation factor, HGF also enhances satellite cell 
proliferation, but inhibits differentiation (in vivo and in vitro).  The timing as well 
as the dose of exogenous HGF is important (Miller et al., 2000).  In Miller et al.’s 
study it was shown that a dose of 50 ng, and not 6.25 ng, HGF could induce 
satellite cell proliferation.  Also, when 50 ng HGF was added every day to 
muscles starting on the day of injury (freeze damage), HGF induced significant 
myoblast proliferation the following day.  However, at day 2 or 3 post-injury, 
myoblast numbers were not significantly increased.   
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Nitric oxide (NO) is also indicated as a role player in the activation of satellite 
cells (Anderson, 2000).  This author has also shown immediate satellite cell 
activation upon muscle damage. Stretching seems to play a very important role in 
initiating the events for satellite cell activation.  Activation of satellite cells is not 
accomplished directly through stretching, but rather indirectly via the release of 
NO and HGF.  Data also indicate that NO is released prior to HGF which then 
activates satellite cells (Tatsumi et al., 2002).   
 
Bischoff was able to stimulate satellite cells to proliferate on whole single fibres 
by adding chick embryo extract (CEE).  This proliferation was assessed by 
following the incorporation of [methyl-3H]thymidine ([3H]TdR) into satellite cells 
(not myonuclei).  The satellite cells also enlarged after adding the CEE.  After 4 
days some of the labelled satellite cells fused with each other, but not with their 
associated fibres (Bischoff, 1986).  In the same study several purified growth 
factors and mitogens were also studied using single fibre-satellite cell units.  Only 
fibroblast growth factor (FGF) was capable of stimulating satellite cell 
proliferation.  However, more recently two other growth factors have been 
implicated.  Insulin-like growth factor I (IGF-I) enhances short-term satellite cell 
proliferation (Chakravarthy et al., 2001) as well as satellite cell migration in vitro 
and in vivo (Lafreniere et al., 2004).  Erythropoietin has been shown to stimulate 
proliferation of C2C12 cell cultures, but to inhibit differentiation of these cells 
(Ogilvie et al., 2000).  Another study has also shown that acidic fibroblast growth 
factor (aFGF) can enhance proliferation and differentiation of satellite cells in 
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vitro (isolated form soleus and tibialis anterior rat muscles - a primary cell 
culture) (Dusterhoft & Pette, 1999). 
 
Another approach to investigate a factor, instead of adding the factor to a culture 
in vitro or injecting it in vivo, is to make use of knockout animals.  By inactivating 
the fibroblast growth factor 6 (FGF-6) gene in mice it has been shown that FGF-6 
may play a critical role in skeletal muscle regeneration after crush injury (Floss et 
al., 1997). This growth factor appears to be a necessary activator of satellite cells, 
and may also possibly play a role in MyoD expression during muscle 
regeneration.  Under normal conditions, FGF-6 mutants (FGF-6 (-/-)) and wild-
type mice did not differ in their skeletal muscle immunohistochemistry pattern, 
myotube ultra-structure, or in their satellite cell morphology.  However, the FGF-
6 mutant appeared to have a slightly higher amount of satellite cells.  After freeze-
crush injury in the wild-type mice these authors showed that mRNAs of FGF-6, 
MyoD as well as myogenin were up-regulated during regeneration.  As early as 4 
days post-injury, new myofibres were seen in the lesion in wild-type mice.  This 
was in contrast to muscle repair in the mutants, where smaller and fewer newly 
formed myofibres and more mononuclear cells were observed.  Two weeks after 
injury, wild-type mice myotubes showed no more signs of differentiation and 
there was almost no indication of any damage.  In comparison, the mononuclear 
cell number in mutants was still high and injury was accompanied by a small 
number of degenerated myotubes, large amounts of collagen (indicating fibrosis), 
and a lack of differentiated myotubes.  At 3 weeks the lesions in wild-type mice 
were completely regenerated, whereas in the mutant mice there were two groups:  
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one presented strong fibrosis with large amounts of mononuclear cells; the second 
had moderate fibrosis with high numbers of degenerated myotubes and 
mononuclear cells.  Interestingly, the typical pathological reaction was detected in 
all FGF-6 mutant mice, but the regeneration response in wild-type littermates 
varied.  In the wild-type mice regeneration progressed very well at days 3-8 with 
complete reconstruction after 2-3 weeks. 
 
f)  Chemotaxis (migration) 
Satellite cells have a good migrating capacity, but not much is known about the 
chemotactic signals involved.  Bischoff (Bischoff, 1997) used an in vitro model to 
investigate the effects (chemotactic activity) of several growth factors and wound 
fluid on satellite cells (isolated from rat skeletal muscle).  Chemotactic activity 
was assessed by migration chambers – the more cells that migrated across the 
membrane dividing the chambers, the higher the chemotactic activity of the 
specific growth factor tested.  Only HGF and transforming growth factor-beta 
(TGF-β) showed chemotactic activity with a maximum activity range of 1-10 
ng/ml for both.  HGF concentrations higher than 10 ng/ml inhibited migration of 
satellite cells.  The reason for higher concentrations causing inhibition is not 
known.  This study was the first to show that HGF might be a satellite cell 
chemoattractant during muscle regeneration.  At 5 ng/ml TGF-β stimulated 
maximum migration but inhibited it to basal level at 50 ng/ml.  This study 
suggests that the chemotactic activity of platelet-derived extracts can be attributed 
at least in part to TGF-β (platelets are a major source of TGF-β (Ganong, 1997a)).  
Crushed muscle extract was also able to stimulate chemotaxis of satellite cells in a 
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dose-dependent manner.  Other factors which had no effect on satellite cell 
proliferation included insulin, dexamethasone, platelet-derived growth factor, 
epidermal growth factor and luteinising hormone.  Taken together, the data of this 
study show that migration of satellite cells is stimulated within strict concentration 
gradients of several soluble factors released during muscle injury.  Some of these 
soluble factors are attributable to the immune response to muscle damage. 
 
g)  Inflammation (macrophages, cytokines, etc) 
In an extreme model of muscle damage it was shown that neutrophils and 
monocytes appeared 8 hours after contusion injury in the rat gastrocnemius 
muscle.  These cells appeared within the basal lamina of necrotic fibres where 
they phagocytose the debris.  The number of these leucocytes increased until the 
end of the observation period of 48 hours.  Following the toxic injury, 
inflammatory cell influx was similar to that in the contusion injury with 
macrophages virtually filling the basal lamina cylinders at 24 to 48 hours 
(Rantanen et al., 1995). 
 
Blood borne macrophages play a key role in the regeneration process (Lescaudron 
et al., 1999).  In addition to removal of debris, these cells also secrete factors such 
as TGFβ, TNFα, IFNα and -β, IL1α and -β (Ganong, 1997a) which may also 
promote repair.  For example, as mentioned before, TGFβ has been shown to play 
a role in satellite cell activity (Bischoff 1997).   
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In the study by Lescaudron et. al. (Lescaudron et al., 1999) tissue from transgenic 
pHuDes-nls-LacZ mice (transgenic mice carrying a lac-Z reporter gene that is 
under control of a truncated human desmin promoter - refer to appendix A for 
more detail) was transplanted into non-transgenic mice and regeneration activity 
of the transplanted tissue investigated in vivo.  Tissue incubated with either 
macrophage inflammatory protein beta (MIP 1-β) or vascular endothelial growth 
factor (VEGF) prior to transplantation, displayed an enhanced infiltration of host 
macrophages.  Only pre-incubation with VEGF increased myotube formation (6-
fold increase) possibly due to an enhanced re-vascularisation which would 
enhance the transport of growth factors to the transplant site.  It may have been 
interesting to analyse not only satellite cells of the donor tissue, but also host 
tissue and investigate fusion of host satellite cells with transplant tissue.  The 
authors did not address the possibility that this enhanced myotube formation in the 
VEGF group could be due to other functional effects of VEGF.  Subsequent 
studies indicate that VEGF stimulates migration of satellite cells, which should 
lead to an increase in myotube formation, and that it may protect these cells 
against apoptosis (Arsic et al., 2004; Germani et al., 2003).   
 
An important finding of the original study was that those mice depleted of 
macrophages (by radiation) did not show any regeneration activity (Lescaudron et 
al., 1999).  This indicates that macrophages do play a key role in the regeneration 
process.  This is of importance in the light of our study as it is believed that 
cryotherapy reduces inflammation (Knight, 1995).  However, it is unclear whether 
extended cryotherapy decreases macrophage infiltration to such an extent that it 
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retards the regeneration process, or whether it reduces secondary injury (Merrick 
et al., 1999; Merrick, 2002) and thus, lessens the required repair.   
 
The rationale for using cold treatment is that it is believed to decrease 
inflammation as well as the chance of secondary injury (Knight, 1995; Merrick et 
al., 1999; Merrick, 2002). However, Yackzan and colleagues (Yackzan et al., 
1984) concluded that ice massage (whether applied immediately, 24 h or 48 h 
after exercise) does not alleviate muscle soreness associated with DOMS.  
However there are certain methodological problems with this study, including the 
fact that the ice massage was applied for only 15 minutes and that this one 
application might not be sufficient to be effective.  Furthermore, due to 
massaging, the muscle was not exposed to the cold treatment for a full 15 minutes. 
 
As discussed by Merrick (Merrick, 2002), although it is suggested that 
cryotherapy may decrease secondary injury, it may be that it only delays the 
second injury phase.  Furthermore, it is difficult to distinguish whether damage 
has occurred by primary or secondary injury.  Although several studies have 
investigated the effect of different cold interventions on DOMS, all these studies 
(including most studies investigating other treatment modalities) have focussed 
only on changes in clinical symptoms of DOMS and or the physical/performance 
parameters.  None of these studies have investigated the effect of cold treatment 
on the muscle recovery process, specifically the satellite cells which are 
responsible for muscle repair.  It is very important for an elite athlete suffering 
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from muscle soreness to alleviate the clinical symptoms, but it is also very 
important that his/her recovery is promoted. 
 
1.2.3.5  Satellite cells in human subjects 
 
a)  Distribution of satellite cells 
A study by Kadi and Thornell has suggested that the number of satellite cells per 
myofibre may be related to the number of myonuclei in human muscle biopsy 
samples (Kadi & Thornell, 2000).  Furthermore, Maier and Bornemann (Maier & 
Bornemann, 1999), who investigated myofibre diameter and satellite cell numbers 
in normal and diseased muscle, demonstrated that in normal skeletal muscle the 
number (frequency) of satellite cells is not influenced by the myofibre diameter.  
In contrast, muscular myopathies (inflammatory, neurogenic, and non-Duchenne 
myopathies) showed a positive relationship with an increase in fibre diameter. 
 
b)  SC in aging muscle 
Post-natally there is generally no increase in muscle fibre number, but rather an 
increase in myofibre length and diameter due to growth and hypertrophy 
respectively.  In animal models it has been shown that fibre hyperplasia can occur 
with resistance training but data are controversial (reviewed by Abernethy et al., 
1994).  Also, exercised-induced hyperplasia in humans is unsubstantiated 
(reviewed by Matoba & Gollnick, 1984; Taylor & Wilkinson, 1986). With an 
increase in fibre diameter the number of myonuclei also increases, and this is due 
to the proliferation of satellite cells and their subsequent fusion with existing 
muscle fibres.  Controversies exist about the decrease in satellite cell number with 
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increasing age.  Roth et al. have not shown any differences between satellite cell 
numbers of healthy young and older men and women (Roth et al., 2000), whereas 
Sajko et al. have indicated that the number of m-cadherin+ satellite cells decreases 
with age (Sajko et al., 2004).  However, in the latter study muscle samples were 
obtained at autopsies (6 - 24 hours post-mortem) which may have influenced the 
outcome of the results.   
 
A further study also demonstrated a significantly smaller satellite cell population 
in the old compared to young men and women (Kadi et al., 2004a).  This 
discrepancy might be due to several factors, including different histochemical 
methods, i.e. electron microscopy (Kadi et al., 2004a; Roth et al., 2000) versus 
immunohistochemistry (Kadi et al., 2004a).  In addition, Roth and his group used 
sedentary subjects, whereas Kadi et al used moderately active subjects.  Although 
the ages of the young subjects were similar, Kadi’s elderly group were older.  
Furthermore, different muscle groups were analysed in the investigations. 
 
c)  Exercise 
Not much is known about the response of satellite cells to exercise, especially in 
humans.  Recent studies (Crameri et al., 2004; Kadi et al., 2004b) have shown 
that one bout of exercise is enough to activate satellite cells.  In the study by 
Kadi’s group, muscle biopsies were taken immediately (within 10 - 60 seconds) 
after the exercise bout (which consisted of one-leg cycle ergometry for 30 minutes 
at 40% and 75% of VO2max) and myonuclei stained positively for myogenin.  In 
contrast, Crameri and her group found no positive staining for myogenin.  
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Crameri and colleagues concluded that one bout of exercise (consisting of one 
bout of high intensity eccentric exercise with one leg:  50 one-leg ‘drop down’ 
jumps from a platform, 8 x 10 maximal eccentric knee extensions at -30 degrees.s-
1 and 8 x 10 maximal eccentric knee extensions at -180 degrees.s-1) might not be 
sufficient to stimulate satellite cells to differentiate.  Apart from baseline biopsies, 
Crameri et al. took biopsies 5 hours post-exercise, and on days 2, 4, and 8 post-
exercise.  Taken together, data from both these studies may suggest that one bout 
of exercise is enough to stimulate transient myogenin protein expression in the 
myonuclei, but that this is unlikely to be sustained and may be completely 
unrelated to satellite cells. 
 
1.2.3.6  Application/Biotechnology 
Due to practical and ethical issues, skeletal muscle regeneration has been studied 
most frequently in animal and cell culture models.  However, although in vitro 
studies have proved to be very helpful in the understanding of satellite cells, 
results are not always applicable to the in vivo situations.  One must bear in mind 
that not only one factor (e.g. growth or stimulating factor, or cytokine) is present 
in a mammalian whole body, but each factor is part of a complicated 
physiological system.  This means that the activity of a factor in vitro versus in 
vivo may be completely different.  Thus there is a need to investigate factors not 
only in vitro, but in conjunction with other factors in vivo to fully understand 
satellite cell activity.  Satellite cell activity can be studied in vivo in different 
myopathies (Bornemann et al., 1999; Laule & Bornemann, 2001).  Although 
myopathies are a serious problem, they are applicable to a smaller percentage of 
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the human population.  It is also necessary to investigate circumstances that are 
applicable to the whole population.  DOMS may be a good model to investigate 
satellite cell activity as most of us have experienced it at some stage in our lives.  
In addition, information on satellite cell activity gathered from such a study would 
also be applicable to understanding satellite cells in general.   
 
In summary, DOMS is associated with muscle micro-injury and upon muscle 
damage the recovery pathway will be switched on.  However, satellite cell activity 
during and after DOMS is not well established.  Currently cryotherapy is a very 
popular treatment used by athletes, but the use of this therapy is unsubstantiated 
by scientific research.  Importantly, so far no human study conducted to 
investigate the effect of cryotherapy on DOMS has investigated the effect it may 
have on skeletal muscle repair.  In fact, no human study so far has addressed the 
effect of any DOMS therapy on muscle recovery at tissue level.  This is very 
important since the competitiveness in today’s sports participation creates the 
need for athletes to recover faster and not just to alleviate their pain levels.  Thus 
the aims of this study were as follows:  
1) To characterise the satellite cell activity in humans with DOMS, as well as 
2) To investigate the effect of an ice application on this satellite cell activity. 
3) To investigate the efficacy of the set of antibodies used in this study, 
making use of an in vitro model, i.e. C2C12 cells under normal conditions. 
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CHAPTER 2:  MATERIALS AND METHODS 
 
2.1  In vivo (Human subjects) 
2.1.1  Subject recruitment & inclusion criteria 
This study was approved by Sub-committee C of the Research Committee of the 
University of Stellenbosch.  Six male human subjects were recruited by means of 
advertisements and word of mouth.  The subjects were informed of the procedure 
verbally and in written form.  They signed an informed written consent before 
they were allowed to start with the protocol.  Subjects were included if they 
fulfilled the following criteria: 
• age: 18 – 35 years 
• regular participation in recreational physical activities, excluding regular 
downhill running or walking 
• informed written consent was obtained 
The exclusion criteria were: 
• regular, systematic training 
• regular participation in competitive events  
• participation in hiking or hill walking in the 3 months prior to the study 
• treatment for an inflammatory condition 
• muscle injury in the previous 3 months 
• a cardiovascular condition 
• informed consent was not obtained 
 
 43
2.1.2  Induction of delayed onset muscle soreness (DOMS) 
At least two weeks prior to inducing DOMS the subjects completed a peak 
treadmill speed (PTS) test.  During this test, both VO2max and maximum speed 
attainable during an incremental treadmill test to fatigue, were determined.  To 
induce DOMS subjects performed a 40-minute intermittent downhill run (DHR) 
protocol.  The protocol consisted of five 8-minute bouts at –10% (-5.7 degrees 
slope) on a motorised treadmill (RUNRACE HC1200; Technogym, Italy).  Each 
bout was followed by a 2 min standing rest.  The speed of the treadmill was set at 
70% (two subjects with VO2max < 50) or 80% (four subjects with VO2max > 50) of 
each subjects’ own PTS.  Subjects were instructed not to exercise for the duration 
of the study after they had completed the DHR.  All laboratory testing, including 
the ice treatment, occurred at an ambient room temperature of 18 oC. 
 
The DHR protocol used in this study was modified from Eston et al. (Eston et al., 
1994; Eston et al., 1996a; Eston et al., 1996b).  To our knowledge all DHR 
protocols have previously made use of an individual’s heart rate (HR) (Byrnes et 
al., 1985b) or predicted maximum heart rate (Eston et al., 1996b), or VO2max 
(Schwane et al., 1983) to determine their DHR treadmill speed.  In our laboratory 
we found that the HR and VO2max drift with time making it difficult to determine a 
constant speed for the test.  Thus, it was decided to use each individual’s PTS to 
determine their individual DHR speed.  The final protocol had been used to 
induce DOMS in a previous unpublished study in our laboratory (I. Neethling, 
Honours student 2002). 
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2.1.3  Ice treatment 
Immediately after cessation of the DHR each subject received their first ice 
application on only one leg.  The ice treatment involved the placing of a plastic 
bag (400 x 340 mm; Jiffy Freezer bag, Transpaco Flexibles) filled with crushed 
ice, weighing approximately 2.5 kg, directly onto the upper leg (quadriceps 
muscle group) and without any interface between the plastic and the skin.  The 
aim was to place the ice pack in a position that included the typical biopsy areas.  
Each ice application lasted 30 minutes and was repeated every two hours, five 
times a day for three days on the same leg.  Subjects received ice treatment for a 
total of three consecutive days, including the day of the DHR (Figure 2.1).  The 
researcher applied all ice treatments to ensure correct application.  The leg 
receiving ice was randomly selected to be the dominant or non-dominant leg.   
 
Subjects were informed not to use any medication for the duration of the study, 
especially after receiving biopsies.   This was to ensure that only the effect of the 
ice treatment would be investigated. 
 
2.1.4  Muscle biopsies 
In total five biopsies were obtained from each subject.  A baseline biopsy was 
obtained from each subject (from the dominant leg) at least four weeks before 
inducing DOMS.  The remaining four biopsies were obtained either on days 1 and 
7 post-DHR (three subjects), or days 2 and 9 post-DHR (three subjects).  At each 
of these time points two biopsies were obtained from a subject, one from each leg 
(treated and untreated leg) (Figure 2.1).   
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Figure 2.1.  Summary of the study design. 
 
All muscle biopsies were performed by the same experienced general practitioner 
throughout the entire study.  Biopsies were obtained from the vastus lateralis 
muscle.  To ensure that post-DHR biopsies were taken at 24-hour intervals these 
biopsies were taken between 7:30-8:00 in the morning.  The location of baseline 
biopsies was determined as follows:  subjects lay on their backs with their upper 
body slightly elevated and with the arms alongside the body; where the thumb 
touched the upper leg the biopsy was taken.  The second pair of biopsies was 
taken 2 cm below that point with the third pair 2 cm above that point.   
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Biopsy procedure:  A biopsy area was cleaned with an alcohol swab before 
commencing with the biopsy procedure.  A local anaesthetic, Xylotox (containing 
2% Lignocaine HCL, m/v, and 1:80 000 noradrenaline) (Adcock Ingram Ltd.), 
was injected (subcutaneously and then intra-muscular) before the incision with a 
scalpel blade was made. The needle biopsy method was used (5 mm Bergström 
biopsy needle (STILLE, Sweden)).  The biopsy was orientated on a piece of cork 
and embedded in a tissue freezing medium (Jung; Leica Instruments GmbH, 
Germany) and frozen in isopentane cooled in liquid nitrogen.  Frozen muscle 
samples were stored at –80 oC until further analysis. 
 
2.1.5  Blood sampling 
Although not directly related to the extent of muscle damage (Manfredi et al., 
1991; Nosaka & Kuramata, 1991), a significant increase in serum CK activity is 
often used in DOMS studies as an indicator that muscle damage occurred 
(Schwane et al., 1983; Tiidus & Ianuzzo, 1983).  Thus, blood samples were 
collected to analyse serum CK activity using an automated enzymatic method. 
The normal range of serum CK activity is 15 – 195 u/L (at 37 oC).   
 
All blood samples were drawn from the forearm vein by a qualified phlebotomist 
in SST (serum separating tube) (BD Vacutainer, Becton Dickinson and 
Company).  Blood samples were collected immediately pre- and post-DHR, and 
on days 1, 2, 7, and 9 post-DHR (Figure 2.1).  All samples were collected between 
7:30-8:00 am (except post-DHR) before biopsies were taken, after a five minute 
rest in the supine position.   
 47
 2.1.6  Muscle soreness 
Soreness was assessed immediately pre-DHR, and on days 1 and 2 post DHR 
(Figure 2.1) before starting the ice treatment sessions of those days.  
Questionnaires (Appendix B) and a muscle pain probe (developed by the 
Department of Electrical and Electronic Engineering, University of Stellenbosch) 
were used to estimate the extent of muscle soreness.  Subjects were asked to use a 
scale of 1-5 to rate their soreness with a score of 1 equalling no pain and 5 
equalling very severe pain (Table 2.1).   
 
The muscle probe can be applied to a small area with different magnitudes of 
force. We chose to apply forces that ranged from 1 kg to 5 kg.  The probe is 
connected to an internal force transducer and the analogue data of the force 
applied are converted to digital data and displayed.  It was not necessary to 
calibrate the muscle probe as the force transducer is very robust (personal 
communication: Mr W. van Rooyen, Central Electronic Services, Stellenbosch 
University). For assessment with the muscle probe, three areas on each leg of a 
subject were marked with a pen.  The three areas were determined as follows:  
with the subject seated and his knee joints flexed 90o, the researcher used a 
measuring tape to measure each subjects’ upper leg length from the mid-
superficial part of the patella to the mid part of the inguinal fold of the hip joint 
(hip joint also flexed 90o).  Then the three areas were marked at 20%, 50%, and 
80% (measured from the mid-proximal patella) of the upper leg length.  With the 
subject still in the seated position, the researcher applied a force equal to 1 kg to 
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each of the three marked areas on the quadriceps muscle group of each leg with 
the probe held 90 degrees to the horizontal plane of the dorsal aspect of the upper 
leg.  As soon as the 1 kg reading was achieved, the probe was removed from the 
leg. Immediately after each force application the subject was asked to rate the 
soreness experienced in the specific area during the force application using the 
same soreness scale as for the soreness questionnaires (Table 2.1).  After 1 kg was 
applied the same procedure was repeated for 2, 3, 4 and 5 kg.  Although the use of 
this muscle probe was not validated, the use of this method to determine muscle 
soreness has been used by other authors (Cleak & Eston, 1992a; Eston et al., 
1996b; Newham et al., 1987; Semark et al., 1999; Tiidus & Ianuzzo, 1983).  
 
2.1.7  Sample analysis   
2.1.7.1  Serum analysis 
Total serum CK was determined by PathCare pathology laboratory (Stellenbosch 
Medi Clinic, South Africa). 
 
Table 2.1.  Rating of perceived pain. 
 
Score Worded equivalent
1 No pain 
2 Slight pain 
3 Moderate pain 
4 Severe pain 
5 Very severe pain 
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2.1.7.2  Immunohistochemistry 
Embedded muscle samples were cut into 8 μm transverse sections with a cryostat 
(Leica CM1100, Leica Microsystems Nussloch GmbH, Germany) at temperatures 
between -20 oC and -22 oC.  Sections were air-dried at room temperature before 
storing at -20 oC.  Three serial sections per slide were cut and eight slides per time 
point for each subject were analysed. 
 
At each time point, two slides for each subject were stained for each of the 
following markers – i.e. two slides per marker at each time point for each subject 
(refer to Table 2.2 for details of the primary antibodies):  CD34, CD56, myoD1 
and myogenin.  Sections stained for myoD1 and myogenin were also co-stained 
for the satellite cell marker m-cadherin.  CD34, CD56, MyoD1 (referred to as 
only MyoD hereafter) and myogenin primary antibodies were raised in mouse, 
and m-cadherin antibody was raised in rabbit.    The immunostaining procedure is 
summarised in Appendix C.  Slides were allowed to thaw before fixing sections in 
100% acetone for 2 minutes (CD34 and CD56) and allowed to dry, or without 
fixing (myoD and myogenin).  Non-specific binding sites were blocked by 
incubating sections with 5% donkey serum at room temperature.  After 30 
minutes the serum was drained off before adding the primary antibody (see Table 
2.2 for dilutions) for four hours (CD34 and CD56) or twenty-four hours 
(myogenin and myoD1) at 4 oC.   
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 Table 2.2.  Primary antibodies used to stain skeletal muscle sections. 
 
 Clone Company [Stock] (μg/ml) Dilution 
CD34 581 BD PharMingen 100 1/200 
CD56 MOC-1 DAKO 170 x 103 1/100 
MyoD1 5.8A DAKO 2303 1/25 
Myogenin F5D DAKO 819 1/25 
M-cadherin H-71 Santa Cruz 200 1/50 
 
Slides were washed with phosphate-buffered saline (PBS, 0.1 M, pH 7.4) before 
adding the biotinylated secondary antibody, raised in horse (1/500, CD34 and 
CD56) or donkey (1/1200, myoD1 and myogenin), for 40 minutes at room 
temperature (refer to Table 2.3 for details about secondary and tertiary 
antibodies).   
 
Table 2.3.  Secondary and tertiary antibodies were all obtained from Vector 
Laboratories, Inc., USA. 
 
 Dilution 
Biotinylated secondary Ab  
Horse anti-mouse 1/500 
Donkey anti-rabbit 1/1200 
Donkey anti-mouse 1/1000 
  
Tertiary Ab  
Fluorescein Streptavidin (FITC) 1/500 
Texas Red Streptavidin   1/500 
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Slides were washed again with PBS whereafter a FITC-labelled tertiary antibody 
(1/500) was added for 30 minutes at room temperature.  The nuclear stain Hoecsht 
(1/200) was added for 10 minutes to the CD34 and CD56 slides.  Slides were 
washed with PBS.  CD34 and CD56 slides were mounted with DAKO 
Fluorescent Mounting Medium.   M-cadherin antibody (1/50) was added to the 
myoD1 and myogenin slides and incubated overnight at 4oC.  The following 
morning slides were washed with PBS before incubation with a biotinylated 
secondary antibody raised in donkey (1/1200) for 40 minutes.  Slides were 
washed 3 times before adding Texas Red-labelled antibody (1/500) for 30 minutes 
at room temperature.  The nuclear marker Hoechst (1/200) was added for 10 
minutes at room temperature before washing with PBS and mounting the slides 
with DAKO Fluorescent Mounting Medium.  During this whole protocol slides 
were enclosed in a black box wrapped in wet towels to keep it in a dark and moist 
environment.  All dilutions were made with PBS. 
 
2.1.7.3  Imaging and image analysis of stained biopsy sections: 
Stained sections were viewed with a microscope (Nikon ECLIPSE E400) set at 
40x enlargement and photos were taken with a digital camera (Nikon DXM1200) 
that added no further enlargement.  Photos were used to count positively stained 
satellite cells as well as total nuclei and myofibre numbers per field of view using 
the computer programme Simple PCI version 4.0 (Compix Inc., Imaging Systems, 
USA).  If necessary, photos were enlarged after importation into Simple PCI to 
assist with identification. Satellite cell data were expressed as the number of 
satellite cells per myofibre. 
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2.1.7.4  Satellite cell counting in muscle biopsy sections 
CD56 and CD34 data: 
As mentioned before counting was done using the Simple PCI programme.  The 
CD56 (or CD34) image (refer to Figures 3.4 and 3.9 for examples) was merged 
with the Hoechst stained photo from the same area.  A CD56 positive stained area 
was only identified positively as a satellite cell if it was co-localised with a 
Hoechst stained nucleus.  The CD34 antibody also stains other cells, including 
hematopoietic cells, thus making it more difficult to specifically identify satellite 
cells.  Because we did not use a co-stain with this antibody, for positive 
identification we also relied on characteristic visible features:  using electron 
microscopy it is clear that a satellite cell appears to make a groove in its 
associated myofibre (Mauro, 1961).  Using immunohistochemistry, this groove 
appears as an indentation (personal communication: Prof L-E Thornell, Umea 
University, Sweden).  
 
MyoD and myogenin: 
The same procedure was followed as with CD56 and CD34 stained slides.  MyoD 
and myogenin are nuclear stains that are easily identified.  When a MyoD (or 
myogenin) nucleus overlapped with that of a Hoechst positive nucleus, the 
separate photos (refer to Figure 3.16 for an example of identifying myogenin+ 
satellite cells) were enlarged to make sure that the MyoD (myogenin) and Hoechst 
nucleus had the same shape.  When the nucleus was identified to be positive for 
both, the following was used to elucidate whether this positive nucleus belonged 
to a satellite cell:  both MyoD (myogenin) and Hoechst images were separately 
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merged with the m-cadherin image.  If the MyoD (myogenin) nucleus was co-
localised with m-cadherin the nucleus was identified to belong to a satellite cell, 
otherwise it was identified to be a myonucleus. 
 
2.1.8  Statistical analysis 
Data for the human study are presented as means ± SD.  Muscle soreness ratings 
(ADL questionnaire) and the serum CK data were analysed using repeated 
measures one-way ANOVA.  The Bonferroni post-hoc test was conducted in 
order to distinguish at which time points the statistical difference was.  The results 
for the muscle probe data are complicated (3 sites; 3 different pressures; 2 legs; 
baseline and 2 days).  Therefore, general statistical tests could not be done on the 
raw data – the sample size was too small for the assumptions made by most 
statistical tests for data with this complex design.  Furthermore, all the muscle 
probe data of a particular subject were dependent on each other in several 
different ways, e.g. over time, for position and for the treated and untreated legs, 
which also contributed to the complexity of this data set.  For this analysis a 
statistician advised the following:  The change in soreness rating (delta) from 
baseline was determined for both time points post-DHR.  The changes at each 
time point post-DHR were then analysed separately for a treatment effect using 
repeated measures one-way ANOVA.  If the error bars of the box-and-whisker 
plots did not overlap with zero, then the change in soreness at that time point was 
considered significantly different from baseline (no change will occur at baseline).  
Thus, the visual results were used to see whether there were time effects.  T-tests 
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(dependent samples) were used to determine the P-values for these visual 
differences.   
 
Due to the small sample size (n=3) non-parametric tests were conducted for the 
muscle biopsy data (CD56 and CD34 data).  The Friedman ANOVA was used to 
test for time effects.  When a time effect was found, the Wilcoxon matched pairs 
test was conducted to determine at which time points a difference existed – the P-
values were then multiplied by three and compared at a significance level of 0.05 
(to follow the same assumption made with a Bonferroni post-hoc test for three 
groups).  Another way to approach this would have been to set the acceptable 
limit for statistical significance at 0.05 divided by 3; the statistical outcome would 
be the same. The effect of the ice treatment was analysed using the Wilcoxon’s 
matched pairs test at each time point separately.  All statistical analyses were done 
with the aid of the computer software Statistica version 6. The level of 
significance was accepted at P ≤ 0.05. 
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2.2  In vitro (C2C12 cell cultures) 
2.2.1  Standardised conditions: 
C2C12 cells (kindly donated by the Cape Heart Centre) were used to investigate 
profiles of specific satellite cell marker expression during the different stages of 
their cell cycle.  These cells were grown and maintained in a basal medium 
consisting of Dulbecco’s Modified Eagles Medium (DMEM) (Highveld 
Biological (Pty) Ltd, RSA) supplemented with 10% fetal bovine serum (FBS) and 
antibiotics (PenStrep, Highveld Biological (Pty) Ltd, RSA) in T75 flasks (75 cm2 
flasks).  When the cells reached about 70% confluence (covering approximately 
70% of the flask’s surface), they were plated onto glass cover slips (22 x 22 mm) 
in each well of 6-well plates.  When these cells on the cover slips, in the 6-well 
plates, reached about 70% confluence they were harvested as either myoblasts 
(day 0 before adding differentiation medium) or they were induced to 
differentiate.  The 10% FBS was substituted with 2% horse serum (donor herd, 
Sigma) to induce differentiation (differentiation medium).  All C2C12 cell 
cultures were incubated at 37 oC in an environment of 95% humidity and 5% CO2, 
and all mediums were changed every second day.  Every apparatus and each tool 
used during the cell culture study were sterilized by autoclaving.   
 
2.2.1.1 Baseline 
This protocol was to set up a baseline for satellite cell markers expression.  Cover 
slips from days 0, 1, 3, 6, and 8 were collected and stained 
immunohistochemically for the different cell-cycle (satellite cell) markers. 
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 2.2.1.2  Immunohistochemistry 
Satellite cell activity was investigated by staining with antibodies against the 
following markers:  CD34 (quiescent), CD56 (activated), MyoD1 (proliferation) 
and myogenin (differentiation), and M-cadherin (all satellite cells) (refer to Table 
2.3 for dilutions and suppliers).  Five cover slips per time point were stained for 
each of the following antibodies, CD34, CD56, MyoD1 and myogenin.  M-
cadherin was used as co-stain for all of these markers.  At each time point cover 
slips were gently lifted out of the wells and washed with sterile PBS before fixing 
with methanol-acetone (1:1, v/v).   These fixed cover slips were stored at -20 oC 
until used to stain for above-mentioned markers. 
 
Table 2.4.  Primary antibodies used to stain C2C12 cells. 
 
 Clone Company [Stock] (μg/ml) Dilution 
CD34 ICO115 Santa Cruz 200 1/200 
CD56 MOC-1 DAKO 170 x 103 1/200 
MyoD1 5.8A DAKO 2303 1/100 
Myogenin F5D DAKO 819 1/100 
M-cadherin H-71 Santa Cruz 200 1/50 
 
 
2.2.1.3  Imaging and image analysis: 
Six photos per slide were captured using a microscope (Nikon ECLIPSE E400) 
and digital camera (Nikon DXM1200) at 20x enlargement.  Staining intensities of 
the different antibodies at the different time points were analysed using the 
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computer software Simple PCI version 4.0 (Compix Inc., Imaging Systems, 
USA).  Data gathered from images of individual markers at specific time points 
were pooled together for statistical analysis of the specific time points and 
individual markers. 
  
2.2.2  Statistical analysis 
Data are presented as means ± SD.  One-way ANOVA, with Bonferroni post-hoc 
test, was used to analyse C2C12 data.  Statistical tests were all done with the aid 
of the Statistica (version 6) programme.  The level of significance was accepted at 
P ≤ 0.05. 
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CHAPTER 3:  RESULTS 
 
3.1  In vivo:  human study 
The subject characteristics for all six subjects are presented in Table 3.1.  
Although age and BMI had little variability, there was quite a range for VO2max.  
Two subjects who did the DHR test at 70% of their PTS had an average VO2max of 
42.7 ± 0.8 ml/min/kg (mean ± SD).  The average VO2max of the remaining four 
subjects who ran at 80% of their PTS during the DHR test was 54.3 ± 2.0 
ml/min/kg.   
 
Table 3.1  Subject characteristics.   
 
Age (yr) 24 ± 3 
Height (cm) 181 ± 8 
Weight (kg) 77 ± 8 
BMI (kg/m2) 24 ± 2 
VO2max  (ml/min/kg) 50.4 ± 6.5 
DHR speed (km/h) 12.0 ± 2.4 
 
Data presented as mean ± SD. 
Abbreviations:  BMI - body mass index; DHR – downhill-run 
 
 
The DHR protocol in this study was that of Eston et al. (Eston et al., 1994; Eston 
et al., 1996a; Eston et al., 1996b), with a single modification (see methods).  To 
our knowledge this is the first study to use a subject’s individual PTS to determine 
his DHR speed.  The muscle soreness indicates that this modified protocol was 
successful in inducing DOMS.  
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 3.1.1  Muscle soreness 
The muscle soreness ratings assessed using the ‘active daily living’ (ADL) 
questionnaire (Appendix B) indicated that subjects experienced significant 
soreness a day after the DHR (Figure 3.1) in both the treated and untreated legs.  
This soreness was sustained for a further 24 hours.     
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Figure 3.1  Soreness ratings (mean ± SD) assessed with the ‘active daily living’ 
(ADL) questionnaire before and after the downhill-run (DHR).  The rating in the 
treated and untreated leg was exactly the same, thus only one line is clearly 
visible.  Statistical analysis:  repeated measures ANOVA, * P<0.01 vs pre-DHR 
(Bonferroni post-hoc test). 
 
In fact, the scores for the treated and untreated legs were exactly the same for all 
subjects at all time points.  Due to the fact that muscle soreness was only assessed 
for two days after the DHR the total number of days that muscle soreness 
persisted could not be determined.   
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Muscle soreness was also determined using the muscle pain probe.  The pain 
probe was used to investigate whether different areas of the quadriceps muscle 
group were affected differently by the DHR.  Force magnitudes of 1-5 kg were 
applied to three areas of the superior aspect of the quadriceps, i.e. proximal 
(80%), middle (50%), and distal (20%).  The percentages in brackets indicate the 
relative distance on an individual’s upper thigh measured from the mid-superior 
edge of the patella to the mid part of the inguinal fold of the hip joint (with the 
subjects seated on a chair with their knee and hip joints bent 90o).  No difference 
in soreness from baseline was experienced when applying 1 or 2 kg.  Only the 
applied pressures of 3-5 kg elicited significant pain.  Only the results of 5 kg 
applied pressure are presented here (please refer to the appendix D for results of 
3-5 kg).  Also, only the results of the middle and distal areas (for 5 kg) are 
presented here.  The reason for the latter is due to the facts that a) we obtained 
biopsies from the middle area of the vastus lateralis and b) muscle damage in 
animal models predominantly occurs at the distal musculo-tendon junction 
(reviewed in Graham, 1990) and a study using DHR to induce DOMS in humans 
subjects, has shown that the distal and proximal musculo-tendon junction of the 
quadriceps femoris is more sensitive to pain than the mid-belly of the quadriceps 
femoris (Baker et al., 1997).  Thus, we considered it important to show a) whether 
significant DOMS was induced in the middle area after the DHR and b) whether 
the distal area experienced more pain.  We found that pain was significantly 
increased in the middle portion at day 2 post-DHR in both the treated and 
untreated legs (Figure 3.2).  No significant treatment effect was found at any time 
point for any of the forces applied.   
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Figure 3.2  The change (rating at time point minus baseline) in pain ratings 
(mean ± SD) determined using the muscle pain probe, applying a force of 5 kg in 
the middle quadriceps (panel A), and (panel B) the distal quadriceps.  The 
absence of error bars indicates a standard deviation of zero.  Statistical analysis:   
t-test for dependent samples, * P < 0.005, # P < 0.05 vs baseline. 
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3.1.2  Serum CK activity 
In addition to inducing muscle soreness this modified DHR protocol also caused a 
significant increase in total serum CK activity on day 1 post-DHR (Figure 3.3A).  
CK activity peaked the day after DHR which was uninfluenced by any muscle 
biopsies (baseline biopsies were completed 1 month previously and day 1 post-
DHR biopsies were taken after blood sampling).  Thereafter it receded toward 
baseline level again.  However, the CK activity results of days 2, 7 and 9 could 
have been affected by the muscle biopsies and hence the dashed line in Figure 
3.3A.  Recovery was significant by day 9 post-DHR.   
 
A muscle biopsy itself will cause an increase in serum CK activity due to the 
muscle damage caused.  In subjects receiving biopsies at 24 h post-DHR, serum 
CK activity did not further increase on day 2 or later.  However, in subjects whose 
biopsies were taken 2 days (48 h) post-DHR, the serum CK activity tended to be 
increased at day 7 (i.e. 5 days post-biopsies).  The significance of this finding is 
not clear as serum samples were not obtained at days 3-6 and 8 post-DHR.  The 
effect of biopsies on serum CK activity is demonstrated in Figure 3.3B.   
 
3.1.3  Satellite cell analysis 
The satellite cell data were obtained by analysing two sections (8 μm apart) from 
each subject’s biopsy, at each time point for each antibody.  Five to six fields of 
view per section were analysed (a few biopsy samples were too small to count 6 
views).   Due to difficulty obtaining a muscle biopsy from the treated leg from one  
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Figure 3.3  Total serum creatine kinase (CK) activity (mean ± SD) of all six 
subjects before and at several time points after the DOMS inducing exercise 
(panel A).  Statistical analysis:  Repeated measures one-way ANOVA, * P < 
0.01, # P = 0.05 (Bonferroni post-hoc test).  Mann Whitney U-test showed no 
significant differences between the group receiving their post-DHR biopsies at 24 
hours and those receiving it at 48 hours (panel B). 
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subject (biopsy sample too small to analyse), the day 7 post-DHR (ICE group) 
could not be statistically analysed.  
 
3.1.3.1  CD34 
CD34 expression in muscle sections was quantified as the number of CD34+ 
satellite cells per myofibre number.  Due to the fact that other cells, including 
fibroblasts and hematopoeitic cells, also express CD34, only CD34+ cells nestled 
close to the sarcolemma and causing an indentation in the myofibre were recorded 
as CD34+ satellite cells (Figure 3.4, white arrows).  Other CD34+ cells that were 
not associated with such an indentation were not counted.  Usually the cells which 
do not make an indentation in a myofibre appear round and/or lie outside the 
myofibre (Figure 3.4, red arrows).  Sometimes a nucleus may seem to make an 
indentation, but the staining for CD34 is not intense enough to be counted as 
CD34+ and also, the nucleus is not surrounded by a very thin layer of CD34+ 
cytoplasm (Figure 3.4, red dashed arrows).  Another example of a CD34+ non-
satellite cell is where there appears to be CD34+ staining and an indentation, but 
there is no CD34+ cytoplasm separating the nucleus and myofibre (Figure 3.4, red 
arrow head).   
 
Only the untreated legs at days 1 and 7 post-DHR showed a time effect (P = 0.05, 
Friedman ANOVA).  CD34+ cell number decreased at day 1 post-DHR in the 
control leg but was not significant on post hoc analysis, whereas in the treated leg 
no decrease at all was apparent (Figure 3.5).  CD34+ satellite cell number in the  
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Figure 3.4  CD34 staining in a biopsy at day 1 post-DHR from the control leg of 
a subject (original magnification x 40).  FITC (green) represents CD34 
expression (panel A, B) and Hoecsht (blue) stains all nuclei (panel B).  The white 
arrows indicate CD34+ satellite cells whereas the red arrows demonstrate CD34+ 
cells not identified as satellite cells (see text). 
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Figure 3.5  CD34+ satellite cell count (SC) normalised for the myofibre number 
(SC/myofibre) (mean ± SD) at days 1 and 7 (D1, D7; panel A), and days 2 and 9 
(D2, D9; panel B) after the DHR.  Statistical analysis:  Wilcoxon matched pairs 
test, with post-hoc significance demonstrated between the two specific data 
points, * P < 0.05.   
 
 
control leg was therefore significantly less compared to the ice leg at day 1 post-
DHR.  This treatment difference was only evident on day 1.  Inter-individual 
variability of CD34 expression is shown in Figures 3.6 and 3.7.  These inter-
individual responses may have abrogated a time and treatment effect in the CD34+ 
satellite cell number.  The minimum and maximum values for the CD34+ satellite  
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Figure 3.6  CD34 expression in muscle sections of individuals at baseline and 
days 1 and 7 post-DHR (mean ± SD for ~12 fields of view); (A) subject 1, (B) 
subject 2, (C) subject 3. 
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Figure 3.7  CD34 expression in muscle sections of individuals at baseline and 
days 2 and 9 post-DHR (mean ± SD for ~12 fields of view); (A) subject 4, (B) 
subject 5, (C) subject 6. 
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cell number per myofibre number were as follows:  baseline (0.01 - 0.18), day 1 
CON (0.05 - 0.13) and ICE (0.10 – 0.24), day 2 CON (0.02 - 0.31) and ICE (0.07 
– 0.20), day 7 CON (0.06 – 0.15) and ICE (0.09 – 0.11), day 9 CON (0.09 – 0.27) 
and ICE (0.09 – 0.22).   
 
3.1.3.2  CD56 
CD56 was used as a marker to investigate the number of activated satellite cells.  
The only time effect found was in the control legs at days 2 and 9 post-DHR (P < 
0.005, Friedman ANOVA).  Also, there was a significant difference between the 
treated and untreated legs after the DHR (Figure 3.8), with muscle from the 
control leg having significant satellite cell activation 48 hours after inducing 
DOMS (Figure 3.8B).  This activation of satellite cells was sustained up to nine 
days after the DHR.  In contrast, muscle from the treated leg showed no 
significant increase in the frequency of activated satellite cells over time.  
Furthermore, at the specific time points days 2 and 9 post-DHR, the treated leg 
had significantly fewer CD56+ cells compared to the untreated leg.   
 
Figure 3.9 shows examples of CD56 expression found in individual fields of view 
at baseline (panel A, B), and in a untreated (C, D) and treated (panel E, F) leg at 
day 2 post-DHR.  As can be seen in panels B, D and F, CD56 is co-localised to 
satellite cell nuclei.   
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As with CD34 expression, there were inter-individual responses to the DOMS-
inducing exercise when the activated satellite cells were analysed (Figures 3.10 
and 3.11).  The following minimum and maximum values were obtained for the 
CD56+ satellite cells per myofibre number:  baseline (0.04 - 0.26), day 1 CON  
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Figure 3.8  CD56 positive satellite cells expressed per myofibre number (CD56+ 
SC/myofibre number) (means ± SD) at days 1 and 7 (D1, D7; panel A) and days 
2 and 9 (D2, 9; panel B) post-DHR.  Statistical analysis: Wilcoxon matched pairs 
test, * P < 0.01, # P < 0.001. 
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Figure 3.9  CD56 expression (green, FITC) in biopsies taken at (A) baseline and 
at day 2 post-DHR in the control (C) and ice leg (E) of the same subject.  The 
photos on the right hand side (B, D, F) correspond to the time points of the 
photos on the left hand side, representing merged images of the CD56 expression 
and that of Hoechst (blue) that stains all nuclei (original magnification x 40).  
Examples of CD56+ satellite cells are indicated by the white arrows. 
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Figure 3.10  CD56 expression (mean ± SD) in muscle biopsy sections of 
individuals at baseline and days 1 and 7 post-DHR; (A) subject 1, (B) subject 2, 
(C) subject 3. 
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Figure 3.11  CD56 expression (mean ± SD) in muscle biopsy sections of 
individuals at baseline and days 2 and 9 post-DHR; (A) subject 4, (B) subject 5, 
(C) subject 6. 
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(0.13 - 0.21) and ICE (0.13 – 0.42), day 2 CON (0.12 - 0.50) and ICE (0.10 – 
0.30), day 7 CON (0.19 – 0.28) and ICE (0.19 – 0.25), day 9 CON (0.21 – 0.47) 
and ICE (0.16 – 0.26).    
   
Figure 3.12 shows the combined data from all subjects for CD34 (Figure 3.12A) 
and CD56 (Figure 3.12B).  In this figure it is apparent that, in the control leg, 
there is a tendency for a decrease in number of quiescent (CD34+) satellite cells at 
day 1 to be followed by an increase in activated (CD56+) satellite cells (day 2 
post-DHR).  However, the same tendency is not visible the treated leg.  Rather, 
there could be a tendency for an earlier increase in CD34+ satellite cell number in 
the ICE condition (day 1 post-DHR), with no activation following.  These 
observations could infer that the treatment with ice abrogates the relation between 
quiescent and activated satellite cells. However, large variability between subjects 
and low subject numbers prevented a clear and unambiguous result.  The data also 
suggest a possible biphasic response in both the CD34 (in treated and untreated 
legs) and CD56 (untreated legs) expression.  However, the importance of 
analysing multiple subjects, time points and fields of view in order to obtain 
conclusive results must be underscored.  Although more subjects at each time 
point would be possible and more time points preferable, this would not be easy to 
achieve.  Similarly, matching biopsies (same subjects) at all time points would be 
preferable, but not ethically achievable. 
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Figure 3.12  CD34 (A) and CD56 (B) data of muscle biopsies grouped together 
for all time points. 
 
Correlation matrixes were used to determine whether possible relationships 
existed between the VO2max and the CD34+ satellite cell numbers at baseline as 
well as the CD56+ satellite cell number at baseline.  No significant correlation was 
found between the CD34+ satellite cell number and the VO2max (r = 0.65, P = 
0.16).  Although not significant (r = 0.78, P < 0.07) the CD56+ satellite cell 
number and VO2max showed a trend for a possible relationship (Figure 3.13).  The 
small sample size (n = 6) may have abrogated the possibility of a significant 
relationship.     
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Figure 3.13  Comparison of the CD56+ satellite cells at baseline and the VO2max.   
 
Furthermore, the satellite cell activation responses (delta CD56, time point minus 
baseline) were determined for early (days 1 and 2 grouped for n = 6) and late 
(days 7 and 9 grouped for n = 6) time points for the control legs.  Some of these 
activation responses were related to other parameters.  The late change in CD56+ 
satellite cell number was significantly (r = 0.93, P < 0.01) related to the ADL 
soreness ratings at day 2 post-DHR (Figure 3.14).   
 
As with the CD56 data, the satellite cell response was also determined for the 
CD34 data (delta CD34) at early and late time points.  A positive relationship was 
found to exist between the early change of CD34+ and the early change of CD56+ 
satellite cell numbers (r = 0.92, P < 0.01) (Figure 3.15A).  The early change in 
CD34+ satellite cell number was also significantly (r = 0.86, P < 0.05) correlated 
to the overall change (late time point minus baseline) in CD34+ cell number 
(Figure 3.15B).  This shows that an early change in CD34+ satellite cell number 
was still evident at the later time point, whether positive or negative.   
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Figure 3.14  The relationship between the late change in CD56 expression and 
soreness at day 2 post-DHR (determined by the active daily living questionnaire 
= ADL rating).  
 
We also recorded the total myofibre-associated nuclei (Hoechst+) expressed per 
myofibre (nuclei/myofibre) in each muscle biopsy section of the control legs 
(Table 3.2).  No time effect of the nuclei/myofibre existed for days 1 and 7 post-
DHR (Friedman ANOVA, P < 0.1), and also for days 2 and 9 post-DHR 
(Friedman ANOVA, P < 0.7).  The early change in nuclei/myofibre showed no 
relationships with neither the early change in CD34 expression (r = 0.46, P = 
0.36) nor the early change in CD56 expression (r = 0.34, P = 0.50).  To be able to 
compare our satellite cell data with that of other studies, we also determined the 
percentages CD34+ and CD56+ satellite cells at each time point for the control 
legs (Table 3.2).  For example, the percentage CD34+ satellite cells was calculated 
as CD34+ satellite cells/(total number of myofibre-associated nuclei) x 100.   
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Table 3.2  Data of the total myofibre-associated nuclei expressed per myofibre 
and the percentage of CD34+ and CD56+ satellite cells for all time points in the 
control legs. 
 
 Baseline Day 1 Day 2 Day 7 Day 9 
Nuclei/myofibre      
%CD34+ 4.4 ± 3.6 3.2 ± 3.2 3.8 ± 3.4 2.9 ± 2.3 5.0 ± 2.3 
%CD56+ 7.1 ± 4.2 7.6 ± 3.9 10.9 ± 6.8 7.3 ± 4.0 11.0 ± 5.3 
 
Footnote:  Data presented as means ± SD. Co-expression of these markers is possible.  
 
3.1.3.3  MyoD and myogenin 
MyoD and myogenin expression was found in both satellite cells (Table 3.3 and 
3.5 respectively) and myonuclei (Table 3.4 and 3.6 respectively).   However, very  
Few positively-stained cells were observed.  The majority of satellite cells 
expressing myogenin were found at day 9 post-DHR.  Figure 3.15 is an example 
of myogenin expression in a nucleus of a satellite cell (also Hoechst+ and 
expressing m-cadherin).  Similar staining was seen with MyoD expression. 
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Figure 3.15  Presentation of the relationships between the early changes in CD34 
expressions between both the early change in CD56 expression (panel A) and the 
overall change (days 7 and 9 minus baseline) in CD34 expression (panel B). 
 
 
 
 
 
 
 
 
 
 80
Table 3.3  Number of MyoD+/m-cadherin+/Hoescht+ satellite cells expressing 
MyoD in individual muscle biopsies. 
 
 Baseline Day 1 Day 2 Day 7 Day 9 
Subject  CON ICE CON ICE CON ICE CON ICE 
1 - 1 -   1 -   
2 - - -   2 -   
3 - - -   - -   
4 -   - 1   - - 
5 -   1 -   - - 
6 -   - -   - - 
 
Footnote:  - indicates 0 observations in the 10-12 fields of view analysed per subject.  1 or 
2 indicates number of MyoD+/m-cadherin+/Hoescht+ cells in the 10-12 fields of view per 
subject.  Cells of the table containing – or nothing indicate no observations or no biopsy 
was taken on that day respectively. 
 
 
Table 3.4  Number of MyoD+/m-cadherin-/Hoescht+  cells non-satellite cells 
expressing MyoD in individual muscle biopsies. 
 
 Baseline Day 1 Day 2 Day 7 Day 9 
Subject  CON ICE CON ICE CON ICE CON ICE 
1 - - -   - 1   
2 - - -   - -   
3 - - -   - -   
4 -   - -   - - 
5 1   - -   - - 
6 -   - -   - 1 
 
Footnote:  see table 3.2 for key to interpretation of the data (MyoD+/m-cadherin-
/Hoescht+). 
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Table 3.5  Number of myogenin+/m-cadherin+/Hoescht+  cells satellite cells 
expressing myogenin in individual muscle biopsies. 
 
 Baseline Day 1 Day 2 Day 7 Day 9 
Subject  CON ICE CON ICE CON ICE CON ICE 
1 - - 1   - -   
2 - - -   - -   
3 - - -   - -   
4 -   - -   - - 
5 -   - -   2 - 
6 -   - -   1 2 
 
Footnote:  see table 3.2 for key to interpretation of the data (myogenin+/m-
cadherin+/Hoescht+). 
 
 
Table 3.6  Number of myogenin+/m-cadherin-/Hoescht+  non-satellite cells 
expressing myogenin in individual muscle biopsies. 
 
 Baseline Day 1 Day 2 Day 7 Day 9 
Subject  CON ICE CON ICE CON ICE CON ICE 
1 - - -   - -   
2 - - 1   - -   
3 - 1 1   - -   
4 -   - -   - - 
5 -   - -   - - 
6 -   - -   - - 
 
Footnote:  see table 3.2 for key to interpretation of the data (myogenin+/m-cadherin-
/Hoescht+). 
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Figure 3.16  Myogenin expressed in the nucleus of a satellite cell (white arrow).  
This image was taken from a muscle section from the control leg at day 9 post-
DHR.  FITC (green) indicates myogenin expression (A), Hoecsht (blue) stains all 
nuclei (B) and Texas Red (red) shows m-cadherin staining (C) (original 
magnification x 40). 
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3.2  In vitro:  C2C12 cells 
The expression profiles of the markers used to analyse satellite cells in vivo were 
assessed in differentiating C2C12 cell cultures.  The aims of this experiment were 
to analyse the activation and differentiation in vitro using a valid satellite cell 
model, as well as to test whether our set of antibodies was successful in staining 
satellite cells at the appropriate, expected times in the cell cycle in these 
differentiating cells.  Apart from testing the validity of the antibodies used in this 
study, we also wanted to investigate the expression patterns of these markers.  
Finally, this model could indicate an increase in CD56 expression which was 
accompanied by a decrease in CD34 and also, a down-regulation in MyoD 
expression preceding an increase in myogenin expression. 
 
The appearance of the C2C12 cells differs at distinct time points of differentiation 
(Figure 3.17).  Before inducing differentiation the cells contain very little 
cytoplasm, but following activation the cytoplasm becomes more abundant.  At 
day 3 these cells appear to form extensions (panel B).  By day 6 both 
differentiation and fusion have clearly occurred (panel C).  At day 8, myotube 
formation as well as myotube alignment is clearly visible (panel D).  
 
The expression of CD34, CD56, MyoD and myogenin was quantified by 
determining staining intensity (Figure 3.18).  A low CD34 expression (Figure 
3.18A) was sustained over the first three days after inducing differentiation, 
though a slight, statistically insignificant elevation seems possible for day 1.   
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Figure 3.17  Differentiation in C2C12 cells: (a) day 1, (b) day 3, (c) day 6, (d) 
day 8.  Myogenin is indicated with FITC (green), nuclei stained with Hoescht 
(blue) and m-cadherin is indicated with Texas Red (red) (original magnification x 
20). 
DC 
 
 
These results are similar to those found in another study (Beauchamp et al., 2000).  
CD34 expression had increased significantly at both days 6 and 8, suggesting an 
increase in the population of quiescent C2C12 satellite cells.  Under control 
conditions (D0), CD56 expression was also low.  Following the differentiation 
stimulus, the expression of CD56 showed a trend to increase until day 6, but 
showed a significant increase at day 8 with day 8 being significantly different to 
all other time points (P < 0.01).  This indicates that, although a small population 
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of C2C12 cells are already activated prior to differentiation, further activation 
occurs in response to the differentiation stimulus (Figure 3.18B), and is highest 
only 2 days after the highest CD34+ staining intensity (although day 7 was not 
assessed).  MyoD expression only increased significantly at day 8 (D0 vs D8, 
Figure 3.18C; P < 0.01), although a trend for an increase could be seen at day 1 
(similar in profile to CD34).  This is surprising in light of the fact that myogenin 
expression (indicating differentiated cells) was also significantly increased at day 
8 (D0 vs D8, Fig 3.18D; P < 0.01).  However, both myogenin and MyoD may 
display a biphasic mode of expression (Figures 3.17C & D) that was not 
synchronised.  The data suggest an increase in myogenin (D3) follows after an 
increase in MyoD.  It is possible that a larger increase in myogenin expression 
may have followed at e.g. day 10 or 12.  Furthermore, within the C2C12 culture 
there may be distinct populations of satellite cells at different stages of the cell 
cycle.  In the current study we did not synchronize the cells prior to 
differentiation.  Hence, some cells may have been responsive at day 1 (MyoD) 
and day 3 (myogenin), but the majority at day 8.  Alternatively proliferation was 
still occurring. 
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Figure 3.18.  Expression of CD34 (A), CD56 (B), MyoD1 (C) and myogenin (D) 
(means ± SD) in C2C12 cells.  Statistical analysis:  One-way ANOVA, * P < 
0.01,     # P < 0.05 (Bonferroni post-hoc test). 
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CHAPTER 4:  DISCUSSION 
 
In vivo 
The aims of the study in human subjects were 1) to induce delayed onset muscle 
soreness (DOMS) in recreationally active individuals using a modified downhill-
running (DHR) protocol, 2) to characterize satellite cell activity in muscle 
biopsies taken from these subjects and 3) to investigate the effect of an ice 
application on this satellite cell activity.  In general, DOMS studies in human 
subjects have most frequently addressed the clinical symptoms and have used 
several serum parameters to investigate the effects of their respective therapeutic 
interventions (e.g. Smith et al., 1994b; Tokmakidis et al., 2003; Yackzan et al., 
1984).  However, although the alleviation of the clinical symptoms of DOMS is 
important, so is the recovery of the affected muscle(s).  To our knowledge this is 
the first study to investigate the effect of cryotherapy on DOMS at the tissue level, 
specifically on skeletal muscle satellite cell activity, in humans.    
 
Several DOMS-inducing protocols have used specialised equipment such as 
eccentric cycle ergometers (Kadi et al., 2004b) or extreme protocols such as 
multiple repetitions of eccentric exercise in a small muscle (e.g. elbow flexors) 
(Paddon-Jones & Quigley, 1997).  Although those models have successfully 
induced DOMS, they do not represent typical exercise patterns in recreational or 
elite athletes.  Therefore, we decided to use a running protocol that could be 
completed within one hour.  It has previously been shown that DHR, but not level 
running, induces DOMS (Pizza et al., 1995; Schwane et al., 1983) thus it was 
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decided to use a DHR protocol.  However, it is important to take into account the 
fitness level of each individual to standardise the intensity of the DHR.  Existing 
DHR protocols make use of individuals’ VO2max or estimated maximum heart 
rates from which to determine a sub-maximal intensity for the DHR (Byrnes et 
al., 1985b; Eston et al., 1996b).  However, past studies report that some, but not 
all individuals’ VO2max’s plateau and hence a linear relationship is not always 
present (Usaj & Kandare, 2000; Zoladz et al., 2002).  But, during incremental 
tests, workload itself increases linearly up to the end of the test.  Thus, we used 
each individual’s peak treadmill speed (PTS) to determine their individual 
submaximal DHR speed.  Our modification to the existing DHR protocols was 
successful, as seen by both the soreness ratings and the serum CK activities post-
DHR (Figures 3.1, 3.2 and 3.3). 
 
Similar to other DHR studies (Pizza et al., 1995; Schwane et al., 1983), the 
perceived muscle soreness (‘active daily living’ questionnaire ratings) was 
significantly increased at 24 and 48 hours post-DHR.  Cryotherapy did not result 
in a difference between the treated and untreated leg, using the soreness data 
collected in response to standardised pressure applied by the muscle probe.  Using 
the same technique, and using a force of 5 kg, we showed that the proximal (80% 
from patella) and middle (50% from patella) sites of the quadriceps muscle had 
more soreness than at baseline on day 2, but the distal area (20% from patella) did 
not differ in soreness from baseline.  It is advised for future studies to evaluate 
soreness (with the muscle pain probe) beyond 48 hours after inducing DOMS, 
because this may elucidate whether a difference between the treated and untreated 
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legs become evident, or not.  The muscle probe results also indicate that 5 kg 
might be the most effective force to be applied to indicate possible pain 
differences.  Because muscle soreness was not assessed beyond two days after the 
DHR, no conclusive deductions can be made about the effect of ice treatment on 
recovery of muscle soreness.   
 
As mentioned in Chapter 1, DOMS is associated with muscle micro-damage in 
the affected muscles and serum CK activity is often used as an indicator of the 
presence of muscle damage.  In our study the serum CK activity was significantly 
elevated one day after DHR, whereafter it started to resolve again (normal serum 
CK activity range from 15 – 195 u/l at 37 oC).   The CK activity response is 
similar to that seen in some other DHR studies, however, the CK activity peak at 
day 1 post-DHR in our study was much greater (almost twofold) when compared 
with some other DHR studies (Pizza et al., 1995; Schwane et al., 1983).  
Although one is tempted to infer that our modification to the DHR protocol 
resulted in a more extreme DOMS-inducing protocol, one cannot do so as it is 
generally accepted that CK activity is not related to the extent of muscle damage 
(Eston et al., 1994; Manfredi et al., 1991; Nosaka & Kuramata, 1991).  
Furthermore, we did not measure the heart rate and VO2max during the DHR, and 
thus were not able to estimate the percentage heart rate or VO2max at which the 
individuals completed their DHR.  Consequently we cannot conclude whether our 
modification to the DHR did in fact result in a more extreme DHR intensity 
relative to the physiological rather than the mechanical maximum.   
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A skeletal muscle biopsy is an extreme form of muscle damage, thus it is feasible 
that this may have influenced the serum CK activities measured after day 1.  In 
our study, only the group receiving their post-DHR biopsies 48 hours after the 
DHR seemed to show an effect of the muscle biopsy on the CK activity at day 7 
post-DHR (5 days after the biopsies) (Figure 3.3B).  However, no significant 
difference was found at day 7 post-DHR between the group receiving their post-
DHR biopsies at 24 hours (6 days after the biopsies), and the group receiving their 
post-DHR biopsies at 48 hours.  The implication of this observation is unclear and 
to clarify this we suggest that in future studies the serum CK activity is 
determined every day for the time-course of the study.  Due to the fact that 
systemic levels of CK activity were measured in our study, we could not 
determine the effect of the ice application on the CK activity as this would have 
required two DOMS subject groups:  one group receiving ice on both legs and the 
other no treatment.  The study design chosen, however, allows for paired 
observations and removes the confounding effect of different inter-individual 
variations in baseline and the response to DHR. 
 
 
CD34 
As far as we know, this is the first study to use CD34 as a marker of quiescent 
satellite cells in vivo in humans.  Other studies have used only CD56 as a satellite 
cell marker without attempting to distinguish between the quiescent and the 
activated satellite cell pools (Charifi et al., 2003; Crameri et al., 2004; Kadi et al., 
2004a; Malm et al., 2000).  However, CD34 has been shown to mark most 
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quiescent adult satellite cells in vitro in cell culture (Beauchamp et al., 2000).  We 
showed almost no time or treatment effects in the CD34 expression at all time 
points in vivo.  Only at day 1 post-DHR the untreated leg expressed significantly 
less CD34+ cells compared to the treated leg.  Other cells in muscle also express 
CD34 making it difficult to identify satellite cells.  Also, we did not use any co-
marker to identify satellite cells, thus it is advised to co-stain with another satellite 
cell marker in future studies.  This may result in time and treatment differences in 
CD34 expression that were not evident in this study.  Alternatively, since great 
care was taken to use morphological features to co-identify CD34+ cells as 
satellite cells, these data may reflect that one bout of DHR does not increase or 
decrease the pool of quiescent satellite cells significantly. 
 
In contrast to CD34, CD56 has been used in at least four other studies to assess 
satellite cells in human muscle biopsies (Charifi et al., 2003; Crameri et al., 2004; 
Kadi et al., 2004a; Malm et al., 2000). 
 
CD56 
The percentage CD56 positive satellite cells at baseline was very similar to the 
percentage found in the tibialis anterior muscle at baseline in a study by Kadi et 
al. in which subjects were recreationally active males (Kadi et al., 2004a). 
However, the percentage of CD56+ satellite cells at baseline in Kadi’s study was 
much higher than that found in other studies (Charifi et al., 2003; Crameri et al., 
2004).  Although controversial, it has been indicated that satellite cell number 
decreases with age in humans (Sajko et al., 2004).  This may explain the very low 
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percentage CD56 satellite cells (vastus lateralis muscle) found in the biopsies of 
the subjects (average age: 73) in Charifi’s study (Charifi et al., 2003).  Another 
difference between these related studies was the normal activity level of the 
subjects.  Crameri’s study used sedentary individuals suggesting that they may 
have a lower number of CD56+ satellite cells than active subjects.  We observed 
large standard deviations, thus large inter-individual differences in both CD34+ 
and CD56+ satellite cell numbers per myofibre at baseline.  The different 
percentage of satellite cells present in baseline biopsies in our study may be 
related to the fitness level of the subjects.  The tendency for a correlation between 
VO2max and CD56+ satellite cell number (P < 0.07) supports a relationship 
between normal activity level and satellite cell activation status.    
 
In our study we report a significant increase in satellite cell activation indicated by 
the significant increase in CD56 positive cells in muscle sections.  This significant 
increase was seen only at days 2 and 9 post-DHR in the control leg, with no 
significant increase at days 1 and 7 post-DHR in the other three subjects.  In 
Crameri et al.’s study (Crameri et al., 2004), two days after a high intensity 
eccentric exercise in one leg of each subject, the percentage CD56+ satellite cells  
((positive cells/positive cells + myonuclear number) x 100) was 6.4% which is 
less compared to our study  when it was 10.7% at day 2 post-DHR.  This smaller 
percentage in Crameri et al.’s study may be due to the difference in exercise 
protocols.  Another possibility is that the change in the percentage CD56 
expression may be similar for both studies, but it was not possible to determine 
this change for Crameri et al.’s study due to unreported baseline values for the 
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exercised leg.  The fact that their subjects were sedentary prior to eccentric 
exercise may also have influenced the satellite cells’ sensitivity to respond to the 
stimulus.  Also, whether satellite cells respond differently to distinct types of 
exercise (e.g. aerobic, anaerobic, power, and high intensity exercise) has not yet 
been investigated.  We cannot explain the difference in activation between the two 
groups in our study.  It is possible that CD56 expression only becomes evident 
two days after DHR.  However, this does not seem likely, because the increase 
was sustained at day 9 post-DHR and yet there was no evidence at day 7 in the 
other subjects.  Possibly inter-individual differences in satellite cell response may 
explain our data (no increase in CD56+ satellite cells in subjects receiving biopsies 
at days 1 and 7 post-DHR) and that of Crameri et al. (Crameri et al., 2004).  To 
our knowledge, it has not been investigated whether an active, fit individual’s 
satellite cells will respond faster to a damage stimulus when compared with a 
sedentary individual.    
 
To further try to understand our results, we determined whether or not there were 
associations between changes in CD34 expression and CD56 expression.  The 
positive relationship between the early changes in CD34+ and CD56+ satellite cells 
(Figure 3.15A) was unexpected.  This finding suggests co-expression of CD34 
and CD56 during the early activation stages of satellite cells.  Thus, this 
possibility of co-expression should be investigated further in vivo.  In Figure 
3.15A, two subjects had a decrease in their CD34+ satellite cells with a decrease 
or no change in the CD56+ satellite cells.  This raises the question of what 
happened to these satellite cells.  Very little is still known about satellite cells, and 
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especially their markers, thus making it difficult to explain this finding.  However, 
we propose a few possible explanations that may explain this finding.  It may be 
that those ‘missing’ satellite cells fused with existing myofibres at an early stage 
or, they were lost due to apoptosis.  However, no correlations were found between 
the total myofibre-associated nuclei (expressed per myofibre number) and the 
early changes in CD34 and CD56 expression, thus apoptosis may not be an 
explanation.  Furthermore, it is also possible that these ‘missing’ satellite cells 
may have migrated to an adjacent area of damage not ‘caught’ by the biopsy.  
Another explanation may be that the ‘missing’ satellite cells represent a 
population that lost their CD34 and CD56 expression due to proliferation, but this 
possibility seems highly unlikely due to the result of very few MyoD+ 
(representing proliferation) satellite cells detected in the muscle sections.  
However, it may be that the antibody we used to detect MyoD was not sensitive 
enough, thus other antibodies should be tested to elucidate whether the latter 
explanation for the ‘missing’ satellite cells holds true. 
 
Ice application 
Cryotherapy is believed to be an effective intervention to decrease inflammation 
(Knight, 1995).   One question is whether a decrease in inflammatory cell 
infiltration, specifically macrophages, would be advantageous to the skeletal 
muscle repair/recovery process.  In fact, it has been shown that at least some 
macrophages are essential for regeneration in muscle transplants in a murine 
model (Lescaudron et al., 1999), but this may not be applicable to all types of 
repair.  Whether this is due to the fact that macrophages have to remove cellular 
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debris and/or that the factors secreted by macrophages can stimulate satellite cell 
activation, is not known. 
 
Several researchers have attempted to investigate the effect of cold therapies on 
the clinical symptoms of DOMS (Paddon-Jones & Quigley, 1997; Yackzan et al., 
1984), but none investigated whether this kind of intervention is advantageous or 
detrimental to the recovery process after DOMS.  In the first study (Paddon-Jones 
& Quigley, 1997), DOMS was induced in both arms of the subjects, whereafter 
only one arm per subject received cryotherapy.  The cryotherapy protocol 
consisted of placing the entire forearm and upper arm in a mixture of ice and 
water (5 ± 1 oC) for 20 minutes immediately after the DOMS-inducing exercise.  
In total, five ice-water immersions were performed with an hour of rest between 
immersions.  Muscle soreness was assessed for 6 days after the exercise bout with 
no significant difference between the treated and untreated arm at any time point.   
Yackzan et al. (Yackzan et al., 1984) also induced soreness in both arms of their 
subjects.  With one of the arms serving as control, the other received an ice 
massage of 15 minutes.  In this study there were three treatment groups:  the first 
group received treatment immediately after the exercise bout (within 3 minutes 
after cessation of the exercise), the second received treatment at 24 hours after the 
exercise bout and the third group received an ice massage at 48 hours after the 
exercise bout.  Muscle soreness was assessed for 3 days after the DOMS-inducing 
exercise with no significant difference between the treated and untreated arms in 
any of the treatment groups.  Although both of these studies suggest that ice 
treatment is not effective in preventing pain, or alleviating pain after DOMS, there 
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were some problems in the design of these studies. In the first study described 
above, the treatment would be more accurately described as cold treatment, rather 
than ice treatment.  In the second study, although the pain rating scale ranged 
from 0-6, the pain induced was maximally 3 and hence likely to be insensitive to 
interventions. It could also be argued that due to the circular movements of the 
massage, total contact time with the ice was less than 15 minutes which may have 
influenced the results.     
 
At day 1 post-DHR there was no significant increase in CD56+ satellite cell 
number in the treated or untreated muscle samples.   However, by day 2 post-
DHR, there was a significant increase in the untreated leg.  This increase was 
prevented by the application of ice.  The implication of this prevention of satellite 
cell activation (at day 2 post-DHR) is that ice application may be detrimental to 
any change in satellite cell status.  In contrast, it has been shown that a bout of 
exercise can activate satellite cells to the same level as seen in the control leg in 
this study (Kadi et al., 2004b; Malm et al., 2000; Crameri et al., 2004).  Taken 
together, these results might infer that the ice application used in this study 
prevented even normal exercise-induced satellite cell activation which could have 
negative implications (negative effect).  This is plausible since the extent of ice 
application in our study was quite extreme.  Alternatively, it could be argued that 
if cold therapy decreased secondary muscle damage (Merrick et al., 1999), the 
extent of satellite cell activation (CD56) required would be less (seen as a positive 
effect).  Merrick has suggested that ice application may decrease the type of 
secondary injury caused by enzymes released due to damaged membranes 
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(Merrick et al., 1999), but this interpretation may not be correct.  It may be that 
cryotherapy retards the progression to cell death caused by primary injury, or that 
it influences other types of secondary injury.  The quantification of both primary 
and secondary injury is difficult and some authors believe it is not possible to 
distinguish between primary and secondary injury (Merrick, 2002).  Thus it is 
important to discover a way to distinguish between these two classes of injury or 
to find another way to investigate the effect of interventions (such as cold therapy) 
on muscle damage.  This highlights the importance of our current study which 
begins to lay a basis for investigating the response of muscle to damage via 
quantification of satellite cell activation, a process that is essential for satellite 
cells to assist in skeletal muscle repair.  Our current study has also raised several 
suggestions for further research.  Future studies should include some 
assessment(s) that could distinguish between these two intracellular effects of ice 
therapy, e.g. quantification of intra-muscular water content (magnetic resonance 
imaging, MRI). 
 
Finally, the use of less extreme ice applications (shorter ice application time 
period and/or fewer application), such as that used by athletes to promote 
recovery, may not have the same effect at tissue level.  Consequently, shorter 
duration times of ice application should also be investigated at skeletal muscle 
tissue level.  This result also raises the question of whether an individual receiving 
ice would respond differently to a second bout of exercise compared to an 
individual receiving no treatment.  It may be important to investigate this, as it 
could be an experimental design to indicate whether satellite cell activation is a 
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requirement for the “second bout” adaptation effect shown by others (Byrnes et 
al., 1985b; Donnelly et al., 1990; Eston et al., 1996b) in response to eccentric 
exercise.   
 
The fact that there were inter-individual differences in satellite cell responses to 
ice application was clear especially when looking at the CD56 expression in the 
muscle sections (Figures 3.6 and 3.7).  This could be explained by differences in 
individual subjects’ adipose tissue in the upper leg area.  Myrer and his colleagues 
(Myrer et al., 2001) have shown that adipose tissue is a very important factor in 
determining the amount of cooling induced by an ice-pack application of 20 
minutes.  Unfortunately no skinfold thicknesses of the upper leg were taken.  In 
future studies we will therefore include skinfold measurements when investigating 
the effect of cryotherapy on DOMS. 
 
CD56 expression in the control biopsies seemed to display a biphasic trend, but 
data are not sufficient to comment on this.  This does emphasise the importance of 
choosing the correct time point(s) to investigate satellite cell-cycle markers in 
order to prevent false deductions.  However, the biphasic response seen in Figure 
3.12B should be considered with caution, because different subjects’ responses 
are presented together in this figure without taking into account that no subject 
had biopsies on all four post-DHR biopsy days.  Nevertheless, the possibility that 
a decrease in CD34+ satellite cells is followed by an increase in CD56+ satellite 
cells, should be investigated.   
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 MyoD and  myogenin 
In the MyoD- and myogenin stained slides we investigated all nuclei (Hoechst+) 
for MyoD and myogenin expression respectively, whilst distinguishing between 
satellite cells (m-cadherin+) and myonuclei (m-cadherin-) expressing these 
markers.  Myogenin positive nuclei (both m-cadherin+ and -) were detected at days 
1 and 9 post-DHR.  Myogenin+/m-cadherin+/Hoechst+ cells were detected in both 
treated and untreated legs.  Also, intra-myofibrillar myogenin+ nuclei that were 
negative for m-cadherin (and therefore are likely to be myonuclei expressing 
myogenin) were also detected.  Cooper and colleagues (Cooper et al., 1999) have 
previously shown in vivo (during regeneration after toxic damage to murine 
muscle) that MyoD can be expressed in myonuclei (m-cadherin-) and not just in 
the nuclei of satellite cells.  In a very recent rat study it has also been shown that 
both MyoD and myogenin are expressed in myonuclei, satellite cells (m-cadherin 
positive) and undefined myogenic cells (Ishido et al., 2004) after overloading in 
the rat plantaris muscle. 
 
Very few studies on muscle samples from human subjects have been done using 
myogenin as a marker for satellite cells.  Kadi et al. (Kadi et al., 2004b) found 
myogenin positive nuclei in biopsy samples taken immediately (within one 
minute) after a bout of exercise in human subjects.  These nuclei were identified 
as myonuclei and not satellite cells by the absence of CD56 expression.  In 
contrast, Crameri and her colleagues (Crameri et al., 2004) did not detect 
myogenin positive nuclei in seven of the eight muscle biopsy samples taken from 
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eight subjects at five hours after an exercise bout.  These contrasting findings may 
be due to the different time points after the exercise bout at which biopsies were 
taken.  Another possibility may be due to the fact that the different research 
groups purchased their myogenin antibody from different companies which may 
have resulted in differences in binding capacities of the antibodies.  Also, the 
dilutions of the antibodies (final concentrations) were not mentioned.  However, 
in Crameri et al.’s (Crameri et al., 2004) study, one subject’s biopsies did have 
myogenin positive nuclei (days 2, 4 and 8 post-exercise) and this subject also 
showed evidence of myofibre necrosis (desmin-negative, dystrophin-negative, but 
fibronectin-positive).  Thus, the latter two possibilities may not have a great 
influence on the controversial results of the two studies.  Unfortunately it was not 
mentioned whether these myogenin positive nuclei were satellite cells or not.  
 
It is unclear exactly when satellite cells that have fused with each other or with 
myofibres lose their satellite cell characteristics (including e.g. m-cadherin 
expression).  Therefore, if the myogenin+/m-cadherin- nuclei in our study are not 
part of the original pool of myonuclei, another explanation may be that they are 
the nuclei of satellite cells that fused with the myofibres and consequently no 
longer have detectable m-cadherin expression, but are still expressing myogenin.   
 
It is difficult to interpret the MyoD and myogenin data in more detail due mainly 
to the limited expression of these myogenic factors and the few time points at 
which biopsies were taken, as well as the small pool of subjects at each time point 
post-DHR.  In future the use of other MyoD and myogenin antibodies should be 
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investigated to make sure that the most suitable antibody is used.  Although 
C2C12 cell cultures do not resemble the in vivo situation, the C2C12 results infer 
that MyoD and myogenin expression may be transiently elevated at first (Figure 
3.18) and may follow a biphasic pattern with greater expression later if stimulated 
to differentiate sufficiently.  This may also hold true for the in vivo situation, and 
if so, it may explain the difficulty in detecting the expression of these two 
markers.   In addition to staining for myogenin as an indicator of the 
differentiation process, it is advised to stain for other markers of muscle damage 
(e.g. fibronectin (Crameri et al., 2004)).  This will aid in elucidating whether 
cryotherapy has prevented secondary injury or suppressed muscle recovery.  It is 
unclear at this time how long after induction of an injury, like the micro-damage 
of DOMS, it takes to regenerate muscle in humans, even without ice therapy.  Our 
study is the first study to take biopsies up to day 9 following DOMS. 
 
As mentioned before, several studies have shown that one bout of exercise is 
capable of activating satellite cells (Kadi et al., 2004b; Malm et al., 2000; Crameri 
et al., 2004).  These three studies involved three different exercise modalities, 
namely one-leg cycle ergometry for 30 minutes at 40% and 75% of VO2max (Kadi 
et al., 2004b), eccentric cycling for 30 minutes at peak workload obtained in 
concentric cycling VO2max test  (Malm et al., 2000) and a bout of one-legged high 
intensity eccentric exercise (one bout of high intensity eccentric exercise with one 
leg:  50 one-leg ‘drop down’ jumps from a platform, 8 x 10 maximal eccentric 
knee extensions at -30 degrees.s-1 and 8 x 10 maximal eccentric knee extensions at 
-180 degrees.s-1) (Crameri et al., 2004).  And it is known that satellite cells are 
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activated upon muscle damage.  Our data showed a positive relationship between 
the late change (late minus early and thus, no influence of the baseline data taken 
into account) in CD56+ satellite cells and soreness experienced at day 2 post-DHR 
(Figure 3.14).  Although muscle damage and soreness ratings may not coincide, 
this finding suggests that muscle damage may be responsible for the sustained 
increase of activated satellite cells at a later time point (day 9 post-DHR), rather 
than the exercise bout itself.  To shed light on this finding, it is recommended for 
future studies to include investigation and quantification of muscle damage, for 
example making use of electron microscopy.   
 
This also raises the question of the actual role of the CD56 expression increment 
after a bout of exercise.  In an in vitro study it was shown that CD56 expression 
enhances fusion of myoblasts to form myotubes (Dickson et al., 1990).  Thus, this 
suggests that CD56 has a role in myoblast fusion.  Therefore, the increase in 
CD56 expression after a bout of exercise may prepare the satellite cells for fusion.  
CD56 has been shown to be expressed in denervated and re-innervated human 
skeletal muscle (Gosztonyi et al., 2001).  Thus, an increase in CD56 expression 
after an exercise bout may change due to a change in neural stimulation or release 
of neural factors during the exercise bout. 
 
In summary, although our data are difficult to interpret due to a lack of other 
related studies, if the soreness ratings were the only data, the conclusion would 
have been that the ice application had no effect on DOMS, but investigating 
DOMS at tissue level shows that cold therapy has an effect.  This is the first study 
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to show an effect of cryotherapy at tissue level in human subjects after inducing 
DOMS.  Thus, this shows the importance of investigating other parameters in 
addition to that of the clinical symptoms and serum parameters.  These results do 
not exclude the use of ice application for shorter time periods or for a shorter time 
course. 
 
 
In vitro 
In our in vitro model of satellite cell differentiation, we were successful in 
showing that the set of antibodies used in this study did stain the C2C12 cells and 
that the binding of these markers to the C2C12 cells occurred at time points in the 
cell cycle corresponding to those expected. 
 
A low CD34 expression was sustained over the first three days following 
induction of differentiation.  These results are similar to those found in another 
C2C12 culture study (Beauchamp et al., 2000).  The significant increase in CD34 
expression at days 6 and 8 suggests an increase in the population of quiescent 
C2C12 satellite cells.  Although it remains to be determined what factors so late in 
differentiation induce this increase, two possibilities exist.  Firstly, proliferation of 
existing quiescent satellite cells or secondly, a return to quiescent status of 
previously activated but unfused satellite cells. 
 
Under control conditions, CD56 expression was similar to that of CD34.  
Following the differentiation stimulus, the CD56 expression showed a steady 
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increase up to day 8.  This indicates that, although a small population of C2C12 
cells are already activated prior to differentiation, further activation occurs in 
response to the differentiation stimulus.  
 
MyoD expression only increased significantly at day 8 of differentiation.  This is 
surprising in light of the fact that myogenin expression was also significantly 
increased at day 8.  Differentiated cells generally show a down-regulation of 
myoD expression (Yoshida et al., 1998).  Our data suggest that within the C2C12 
culture, there may be distinct populations of satellite cells at different stages of the 
cell cycle.  This shows the need to analyse for other markers of proliferation and 
also time points after day 8 to determine at what point proliferation may be 
decreased.   
 
In the current study we did not synchronise the cells prior to the differentiation 
stimulus.  Thus, the time course of CD34, CD56, MyoD and myogenin expression 
should also be determined with synchronisation of C2C12 cells prior to induction 
of differentiation to elucidate possible differences in expression of the different 
cell cycle markers in synchronised versus unsynchronised cells.  Another 
explanation for the non-significant trends in expression patterns could be due to 
the fact that different cover slips with plated cells were analysed at each time 
point for each of the different satellite cell markers.  This can be resolved by 
doing more experiments (with different batches of C2C12 cells) as has been done 
in this study.  A further recommendation would be to also include nuclear counts 
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and to normalise the staining intensities of the different antibodies (at the different 
time points) relative to the number of nuclei.   
 
Both MyoD and myogenin seemed to display a biphasic mode of expression.  To 
investigate this possible biphasic expression it would be necessary to increase the 
sample size and to make use of other investigative techniques, such as Western 
blotting.   
 
So far it is not known what the direct effect of cold temperatures might be on 
satellite cell activity.  This could be investigated in vitro using a cell line, e.g. 
C2C12 cells, to investigate certain cell cycle markers after different durations of 
exposure to decreased temperatures (resembling the temperatures reached in 
skeletal muscle after different cryotherapies).  However, the control model should 
first be more clear and consistent with regard to synchronised versus non-
synchronised cultures and whether markers are expressed biphasically, or not. 
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CHAPTER 5:  SUMMARY 
 
It is important to understand satellite cell activity in the healthy individual as this 
will aid in understanding the shortcomings of satellite cells in different 
myopathies, as well as in aging.  For this purpose, it is appropriate to investigate 
the muscle phenotype associated with muscle soreness at cellular and tissue level.  
Since muscle soreness is not correlated very well with serum CK activity and it 
resolves early after micro-damage, it cannot serve as a marker for satellite cell 
activation or muscle repair.  Therefore, analysis of biopsies is important when 
investigating the effect of an intervention.  This is the first study to investigate the 
effect of an ice application on satellite cell activity in human subjects.  We have 
shown that an ice application of three days, as used in this study, may delay 
muscle recovery after DOMS.  However, it does not discredit the use of ice for 
shorter durations or application times.  Further studies are necessary to investigate 
time points later than 9 days after a DOMS-inducing exercise.   
 
Furthermore, we did establish a baseline differentiation model for C2C12 cell 
cultures.  In future, we can use this model to explore the effects of several 
interventions on satellite cell activity.  One of these interventions could include 
investigating the direct effect of decreased temperatures on satellite cell activity.   
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Appendix A:  Detecting β-galactosidase with X-gal 
β-galactosidase (lactase) is an enzyme isolated from E. coli.  LacZ is a subunit of 
β-galactosidase, i.e. it is a β-galactosidase monomer.  β-galactosidase hydrolyses 
5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside (X-gal), forming a blue 
precipitate.  This characteristic can be used to monitor genetic activity 
(transcription) (1).  For example, transgenic animals carrying a lacZ reporter gene 
under the control of a desmin promoter can be used to detect any activation and 
activity of the desmin gene (2).  If the desmin gene is activated, or is active, β-
galactosidase will be expressed.  This means that β-galactosidase is targeted to the 
nucleus, thus in the presence of X-gal the nuclear product will become blue if the 
desmin gene is active.  This technique can also be used to monitor other genes’ 
activities.  
 
1.  Garrett, R.H. & Grisham, C.M. (1999).  Biochemistry, 2nd ed. Saunders College Publishing, 
USA. 
2.  Lescaudron, L., Peltekian, E., Fontaine-Perus, J., Paulin, D., Zampieri, M., Garcia, L., & 
Parrish, E. (1999). Blood borne macrophages are essential for the triggering of muscle 
regeneration following muscle transplant.  Neuromuscul .Disord. 9, 72-80. 
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Appendix B:  Muscle soreness questionnaires 
 
Muscle soreness (“rating of perceived pain”) 
 
Subject code:                         Starting date: 
Dominant leg: 
 
Muscle Pain 
Hours from 
exercise 
protocol 
Pain during 
ADL 
 Left Right 
0   
24   
48   
 
 
“Rating of perceived pain” 
1 no pain 
2 slight pain 
3 moderate pain 
4 severe pain 
5 very severe pain 
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 Hours from exercise protocol: ..…. 
 
Pressure pain (pressure probe) 
 
Subject code:                           Starting date: 
Dominant leg: 
 
Muscle Pain 
 1 kg 2 kg 3 kg 4 kg 5 kg 
Part of 
muscle 
L R L R L R L R L R 
A           
B           
C           
 
 
A groin 
B middle 
C knee 
 
 
“Rating of perceived pain” 
1 no pain 
2 slight pain 
3 moderate pain 
4 severe pain 
5 very severe pain 
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Spierseerheid (“skatting van waargenome pyn”) 
 
Proefpersoon kode:                          Aanvangsdatum 
Dominante been: 
 
Spierpyn 
Ure vanaf 
oefen 
protokol 
Pyn 
gedurende 
ADL 
 Links Regs 
0   
24   
48   
 
 
“skatting van waargenome pyn” 
1 geen pyn 
2 effense pyn 
3 matige pyn 
4 erge pyn 
5 baie erge pyn 
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        Ure vanaf oefen protokol: ..…. 
 
Drukpyn (druksondeerder) 
 
Proefpersoon kode:              Aanvangsdatum: 
Dominante been: 
 
Spierpyn 
 1 kg 2 kg 3 kg 4 kg 5 kg 
Deel van 
spier 
L R L R L R L R L R 
A           
B           
C           
 
 
A lies 
B middel 
C knie 
 
 
“skatting van waargenome pyn” 
1 geen pyn 
2 effense pyn 
3 matige pyn 
4 erge pyn 
5 baie erge pyn  
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Appendix C:  Immunohistochemical staining diagram. 
 
5% serum at RT, 30’
Biotinylated secondary anti-mouse Ab at RT, 40’ 
Primary Ab at 4 oC, 4h or overnight
FITC-labelled tertiary Ab at RT, 30’
1/50 M-cadherin at 4 oC, overnight
1/1200 Biotinylated donkey anti-rabbit Ab at RT, 40’ 
1/500 Texas Red-labelled tertiary Ab at RT, 30’ 
1/200 Hoecsht at RT, 15’
Figure 1.   Flow diagram of the general immunohistochemical staining protocol 
followed in this study for both skeletal muscle biopsy sections and C2C12 cells. 
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Appendix D:  Muscle probe (3 – 5 kg) results 
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Figure 1  Changes in soreness ratings (mean ± SD) using the muscle probe while 
applying a force of 3kg.  In panel C, the absence of change indicates the absence 
of soreness.  Statistical analysis:  repeated measures one-way ANOVA, analysing 
each time point separately and t-tests (dependent samples).  Statistical analysis 
(comparing each time point with baseline): t-test for dependent samples, * P < 
0.05. 
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Figure 2   Changes in soreness ratings (mean ± SD) using the muscle probe while 
applying a force of 4kg.  Statistical analysis (comparing each time point with 
baseline): t-test for dependent samples, * P < 0.05. 
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Figure 3   Changes in soreness ratings (mean ± SD) using the muscle probe while 
applying a force of 5kg.  Statistical analysis (comparing each time point with 
baseline): t-test for dependent samples, * P < 0.05, # P < 0.005. 
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